var title_f33_15_34032="Ileocolic pedicle laparoscopic view";
var content_f33_15_34032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ileocolic pedicle laparoscopic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the dissection of the mesentery overlying the ileocolic pedicle. The procedure is being performed laparoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34032=[""].join("\n");
var outline_f33_15_34032=null;
var title_f33_15_34033="Pseudogout";
var content_f33_15_34033=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pseudogout (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/15/34033/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34033/contributors\" id=\"au99\">",
"       Michael A Becker, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/15/34033/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34033/contributors\" id=\"se4166\">",
"       H Ralph Schumacher, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/15/34033/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34033/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/15/34033?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT DEFINITION",
"     </span>",
"    </p>",
"    <p>",
"     Pseudogout is a form of arthritis that causes sudden attacks of joint pain and swelling. The prefix \"pseudo\" means appearing like something else; the term &ldquo;pseudogout&rdquo; is commonly used because the symptoms of the disorder are very similar to those caused by gout. Gout is an arthritis caused by urate (sometimes referred to as uric acid) crystals. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"      \"Patient information: Gout (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although the two disorders can cause similar symptoms, patients with pseudogout are treated somewhat differently than patients with gout (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Pseudogout treatment'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Pseudogout can cause sudden attacks of joint pain, swelling, and warmth. An attack can last for days or even weeks. The knee is affected in over 50 percent of patients with pseudogout; however, the disorder can also affect the ankles, feet, shoulders, elbows, wrists, or hands. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"      \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT CAUSES AND RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Pseudogout develops in some people in response to the presence of calcium pyrophosphate dihydrate (CPPD) crystals in the joints. The crystals first develop in the joint cartilage and eventually move to the lining of the joint (also called the synovium) or into the joint fluid where they cause inflammation; this causes pain and swelling. In most people with pseudogout, it is not known exactly why CPPD crystals form in the joints. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6375?source=see_link\">",
"      \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some people, particularly older adults, have CPPD crystals in their joints (chondrocalcinosis) but never experience symptoms of pseudogout. Up to 50 percent of people age 90 have chondrocalcinosis.",
"    </p>",
"    <p>",
"     In addition to older age, there are several other factors that increase the risk of accumulating CPPD crystals in the joints, including:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Joint trauma",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have previously experienced a significant injury to or surgery on a joint have an increased risk of developing CPPD crystal deposits.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Genetics",
"     </span>",
"     &nbsp;&mdash;&nbsp;People can inherit a predisposition to CPPD crystal deposition (called \"familial chondrocalcinosis\"); these people are more likely to develop pseudogout or other features of calcium pyrophosphate crystal deposition disease earlier in life.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Excess iron",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with a genetic disorder called hemochromatosis, which causes the body to store excess iron, are at an increased risk of developing CPPD crystal deposits. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=see_link\">",
"      \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other related disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several other diseases of metabolism or endocrine glands are associated with calcium pyrophosphate crystal deposition disease. These include hyperparathyroidism (overactive parathyroid glands), hypophosphatasia (an inherited metabolic bone disorder), hypomagnesemia (low levels of magnesium in the blood), Gitelman's syndrome (an inherited kidney disorder), and possibly others.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     A healthcare provider can confirm or rule out a diagnosis of pseudogout by performing an examination and tests. In many patients, a sample of joint fluid is obtained in order to determine whether CPPD crystals are present and to exclude arthritis due to other causes, such as gout or joint infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Synovial fluid analysis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Synovial (joint) fluid is obtained under sterile conditions through a needle inserted into the affected joint. The fluid is then analyzed to determine if CPPD crystals or infection are present. The presence of CPPD crystals in a patient with joint pain and inflammation suggests pseudogout, whereas urate crystals suggest gout.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Imaging (x-rays)",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may examine the painful joint(s) by taking x-rays. This can reveal calcium-containing crystal deposits in the cartilage, a condition known as chondrocalcinosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     CPPD crystal deposition disease can lead to rapidly progressing osteoarthritis, caused by wearing down of the joint cartilage, bone cysts or spurs, and even fractures. These changes may occur in joints not usually involved in osteoarthritis, such as the knuckles and wrists.",
"    </p>",
"    <p>",
"     Although treatment of pseudogout episodes can shorten the duration of the attack, treatment may not decrease the risk of developing a more chronic arthritis that in most ways resembles osteoarthritis. Treatment of this chronic arthritis is, thus, similar to that used for osteoarthritis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"      \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no treatment that can completely remove or prevent the formation of calcium pyrophosphate dihydrate (CPPD) crystals. However, the joint pain and swelling generally resolve with treatment, including the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Joint aspiration and/or injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;A clinician may insert a needle into the affected joint to remove the fluid and crystals that have accumulated. This can help to relieve pressure and pain. An injection of glucocorticoids (steroids) into the joint may relieve the associated joint inflammation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Oral medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Joint aspiration or injection is usually preferred when one or two joints are affected but may not be recommended if more than two joints are affected. In this case, an oral medication (NSAIDS, oral glucocorticoids, colchicine) may be preferred.",
"    </p>",
"    <p>",
"     Taking an NSAID such as ibuprofen (Advil&reg;, Motrin&reg;), indomethacin (Indocin&reg;), or naproxen (Aleve&reg;, Naprosyn&reg;) can help to relieve symptoms of pain and inflammation. Prescription-strength tablets (as opposed to over-the-counter tablets) may make it more convenient to take the relatively high doses of NSAIDs that are needed to control an attack. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Joint immobilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients may be advised to avoid weight bearing (walking or running if the legs or feet are involved), to avoid excessive movement, and to limit activity for a period of time to minimize pain and swelling. In some cases, a temporary splint will be recommended to limit joint movement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Treatment of related conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the CPPD crystal deposits are caused by a separate disorder (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Other related disorders'",
"     </a>",
"     above), that condition may require treatment. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18134?source=see_link\">",
"      \"Treatment of calcium pyrophosphate crystal deposition disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PSEUDOGOUT PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     For patients who experience frequent episodes of pseudogout, a healthcare provider may prescribe daily colchicine. Use of this medication, which is also often used to treat or prevent gout, can reduce the number of pseudogout attacks. The benefits and risks of preventive therapy should be discussed with a healthcare provider. The cost of prophylactic use of colchicine may be an issue for many patients and their clinicians. The manufacturer offers a program to defray the cost for eligible patients (ColCrys prescription assistance program [PAP] application available at: www.needymeds.org [Accessed on March 14, 2012]). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"      \"Patient information: Gout (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pseudogout is a form of arthritis that develops in people with deposits of calcium pyrophosphate crystals in joints.",
"      </li>",
"      <li>",
"       The symptoms of a pseudogout attack include joint pain, swelling, and warmth, often with impaired use of the affected joint. (See",
"       <a class=\"local\" href=\"#H2\">",
"        'Pseudogout symptoms'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       The treatment of pseudogout is aimed at the relief of symptoms. This may include nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation, the removal of fluid",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       injection of steroids in the joint to alleviate pressure and reduce inflammation,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       immobilization (rest) of the affected joint. If the pseudogout is caused by a separate disorder, treating that condition may be necessary to prevent complications of the related disease; this may not affect the course of pseudogout. (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Pseudogout treatment'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Some patients who suffer from frequent attacks of pseudogout may be given a medication called colchicine to help prevent future episodes. (See",
"       <a class=\"local\" href=\"#H17\">",
"        'Pseudogout prevention'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804517982\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292594076\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/3/11314?source=see_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/9/10386?source=see_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292594093\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=see_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/29/21975?source=see_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6375?source=see_link\">",
"      Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18134?source=see_link\">",
"      Treatment of calcium pyrophosphate crystal deposition disease",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nih.gov/niams/\">",
"        www.nih.gov/niams/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of",
"       <span class=\"nowrap\">",
"        Rheumatology/Association",
"       </span>",
"       of Rheumatology Health Professionals",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/15/34033/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/15/34033?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Rosenthal AK, Ryan LM. Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. In: Arthritis and Allied Conditions, 15th, Koopman WJ, Moreland LW (Eds), Lippincott, Williams and Wilkins, Philadelphia 2005. p.2373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34033/abstract/2\">",
"      Bong D, Bennett R. Pseudogout mimicking systemic disease. JAMA 1981; 246:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34033/abstract/3\">",
"      Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34033/abstract/4\">",
"      O'Duffy JD. Clinical studies of acute pseudogout attacks: comments on prevalence, predispositions, and treatment. Arthritis Rheum 1976; 19 Suppl 3:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34033/abstract/5\">",
"      Fam AG, Topp JR, Stein HB, Little AH. Clinical and roentgenographic aspects of pseudogout: a study of 50 cases and a review. Can Med Assoc J 1981; 124:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34033/abstract/6\">",
"      Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986; 13:804.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_15_34033=[""].join("\n");
var outline_f33_15_34033=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PSEUDOGOUT DEFINITION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PSEUDOGOUT SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PSEUDOGOUT CAUSES AND RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PSEUDOGOUT DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PSEUDOGOUT COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PSEUDOGOUT TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PSEUDOGOUT PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34034="Supracondylar flexion fx";
var content_f33_15_34034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supracondylar flexion fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexion mechanism. Flexion-type fractures usually result from a blow to the posterior aspect of the elbow. The obliquity of the fracture line may be opposite that of an extension type. The large blue arrows demonstrate the usual direction of displacement of the fragments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34034=[""].join("\n");
var outline_f33_15_34034=null;
var title_f33_15_34035="Defibulation 6";
var content_f33_15_34035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibulation (reversal of female genital infibulation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Step 6: Completed defibulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34035=[""].join("\n");
var outline_f33_15_34035=null;
var title_f33_15_34036="Omalizumab: Patient drug information";
var content_f33_15_34036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Omalizumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     see \"Omalizumab: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=see_link\">",
"     see \"Omalizumab: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xolair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xolair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat moderate to very bad asthma. You may not see your signs get better right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to omalizumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise your chance of cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is",
"       <b>",
"        not",
"       </b>",
"       helpful during an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin every 2 to 4 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11510 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34036=[""].join("\n");
var outline_f33_15_34036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203365\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020237\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020239\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020238\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020243\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020244\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020246\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020241\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020242\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020247\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020248\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=related_link\">",
"      Omalizumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/57/38805?source=related_link\">",
"      Omalizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34037="Bipolar stain of Yersinia pestis";
var content_f33_15_34037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wayson stain of Yersinia pestis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the characteristic \"safety pin\" appearance of the bacteria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Available at: file://www.cdc.gov/ncidod/dvbid/plague/wayson.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34037=[""].join("\n");
var outline_f33_15_34037=null;
var title_f33_15_34038="Types retinal vein occl";
var content_f33_15_34038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Types of retinal vein occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Black arrows show the sites of retinal vein occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34038=[""].join("\n");
var outline_f33_15_34038=null;
var title_f33_15_34039="Evaluation of the adult with polyarticular pain";
var content_f33_15_34039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the adult with polyarticular pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34039/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/15/34039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarticular pain in an adult is encountered frequently in clinical practice. The causes include various self-limited illnesses and others that are potentially disabling and life-threatening. The history and physical examination generally provide the most useful diagnostic information; supporting or confirmatory data are obtained from laboratory and imaging studies or, more rarely, from tissue biopsy. A complete history and physical examination are appropriate for all patients presenting with polyarticular joint pain since this symptom may be the initial manifestation of a systemic illness.",
"   </p>",
"   <p>",
"    The list of causes of polyarticular pain is lengthy and includes, but is not limited to, the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polyarthritis (",
"      <a class=\"graphic graphic_table graphicRef74266 \" href=\"mobipreview.htm?31/60/32716\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral arthritis (",
"      <a class=\"graphic graphic_table graphicRef73403 \" href=\"mobipreview.htm?15/52/16203\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Postinfectious or reactive arthritis",
"     </li>",
"     <li>",
"      Fibromyalgia",
"     </li>",
"     <li>",
"      Multiple sites of bursitis or tendinitis",
"     </li>",
"     <li>",
"      Soft tissue abnormalities",
"     </li>",
"     <li>",
"      Hypothyroidism",
"     </li>",
"     <li>",
"      Neuropathic pain",
"     </li>",
"     <li>",
"      Metabolic bone disease",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic possibilities can be narrowed substantially depending upon whether or not arthritis is present (",
"    <a class=\"graphic graphic_algorithm graphicRef79481 \" href=\"mobipreview.htm?14/50/15136\">",
"     algorithm 1",
"    </a>",
"    ). Among those in whom there are symptoms and signs of synovitis, the further evaluation is limited to those diseases which cause polyarthritis. In the absence of clear cut arthritis, the focus shifts to nonarticular sources of pain.",
"   </p>",
"   <p>",
"    Despite the lengthy list of diseases that cause polyarthritis, many patients with inflammatory arthritis appear to have only one of a few possible disorders. Among over 200 patients with early synovitis (defined as less than one-year duration) evaluated at one academic center, 60 percent were diagnosed with either rheumatoid arthritis or a spondyloarthropathy at presentation or during the following year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/3\">",
"     3",
"    </a>",
"    ]. The prognosis is relatively good for those who remain unclassifiable, with nearly one-half of such patients undergoing remission and not requiring any pharmacologic therapy at follow-up at one year.",
"   </p>",
"   <p>",
"    This topic review will address polyarticular joint pain in adults. Evaluations of the adult with monoarticular pain and of children with joint pain are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14057?source=see_link\">",
"     \"Evaluation of the child with joint pain or swelling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the information obtained in the history is seldom sufficient to lead to a specific diagnosis, it allows substantial reduction in reasonable options. An acute presentation with migratory arthritis and fever, for example, is characteristic of rheumatic fever, disseminated gonococcal infection, and viral arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Musculoskeletal emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of polyarticular pain begins by ruling out potential musculoskeletal emergencies. These conditions generally have an acute presentation and are more commonly associated with monoarticular or oligoarticular pain. Some of these emergencies, however, can be seen in patients with polyarticular pain, and failure to make the correct diagnosis could lead to permanent harm to the patient. Important historical points include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hot or swollen joints may suggest infection (although bacterial infection more commonly presents with acute monoarthritis).",
"     </li>",
"     <li>",
"      Constitutional symptoms (fever, weight loss, malaise) are nonspecific but raise the suspicion of infection or sepsis.",
"     </li>",
"     <li>",
"      Joint pain greater than expected from physical findings may be a symptom of a compartment syndrome.",
"     </li>",
"     <li>",
"      Burning pain, numbness, or paresthesia may suggest an acute myelopathy, radiculopathy, or neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Joint symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to obtain a detailed history of the character of the joint pain, including pain quality, time of onset, exacerbating or remitting factors, and duration.",
"   </p>",
"   <p>",
"    The quality of the pain may be useful in distinguishing musculoskeletal from neurologic causes. The latter is suggested when pain is &ldquo;burning&rdquo; or is accompanied by numbness or paresthesias. Neuropathic pain is also likely to be constant, to be intensified at night, and to be unrelated to motion. However, it is important to remember that an individual patient may experience more than one type of pain. As an example, patients with rheumatoid arthritis (RA) frequently have neuropathic arm pain due to carpal tunnel syndrome.",
"   </p>",
"   <p>",
"    The two main categories of arthritis, inflammatory and noninflammatory, can often be distinguished based upon the character and distribution of joint pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In virtually all forms of inflammatory arthritis, symptoms may worsen with immobility (&ldquo;morning stiffness&rdquo;).",
"     </li>",
"     <li>",
"      In contrast, the pain of osteoarthritis (OA), the most common type of noninflammatory arthritis, is usually aggravated by motion and weight-bearing and is relieved by rest.",
"     </li>",
"     <li>",
"      The joint involvement in RA is usually symmetrical, whereas asymmetry is frequent in OA, especially in the large joints. Problems such as bursitis, tendinitis, or sprains and strains are also asymmetrical in most cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of symptoms may also be helpful. Synovitis that has been present for less than six weeks could represent either a viral arthritis or systemic rheumatic disease, whereas a longer duration would increase the likelihood of the latter. The ability to accurately classify patients with early inflammatory arthritis is difficult. In one study of 211 patients with recent onset synovitis, 36 percent could not be classified and were designated as having &ldquo;undifferentiated arthropathy&rdquo; after follow-up of 33 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of extraarticular symptoms may help to narrow the differential diagnosis. Weakness suggests a neurologic or muscle problem. On the other hand, signs and symptoms of multisystem involvement (fatigue, rash, adenopathy, alopecia, oral and nasal ulcers, pleuritic chest pain, Raynaud phenomenon, or dry eyes and mouth) are common in patients with systemic rheumatic diseases. Fever, night sweats, and weight loss may also suggest systemic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other historical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of the history should focus on the usual areas, including past medical history, family history, social history, and system review. Particular attention should be paid to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional capacity &mdash; This includes assessing the patient&rsquo;s ability to perform usual activities of daily living. Changes in functional status may lead to depression, anxiety, and loss of independence.",
"     </li>",
"     <li>",
"      History of joint injury &mdash; A past medical history of previous trauma, fracture, or surgical procedures on symptomatic joints may help identify the cause of pain.",
"     </li>",
"     <li>",
"      Risk factors for or a history of infection &mdash; For example, exposure to or past infection with viral hepatitis, parvovirus, or Lyme disease could be the cause of a patient&rsquo;s arthralgia.",
"     </li>",
"     <li>",
"      A complete medication list &mdash; A review of medications may lead to a specific diagnosis, such as drug-induced lupus, or may alter treatment choices.",
"     </li>",
"     <li>",
"      Psychologic state and social support system &mdash; The more chronic conditions can greatly affect the life of the patient and his or her family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a complete history, the physical examination is used to further narrow the differential diagnosis. As an example, acute lower extremity pain may have many causes; however, septic arthritis, crystal-induced arthritis, or fracture should be suspected when the pain results in inability to bear weight, or is associated with soft tissue swelling and other signs of inflammation extending far above or below the involved joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Joint examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important objective of the physical examination is to establish the presence or absence of synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ]. Detecting synovitis limits the differential to the inflammatory arthritides and systemic rheumatic diseases. The hallmarks of synovitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soft tissue swelling",
"     </li>",
"     <li>",
"      Warmth over a joint",
"     </li>",
"     <li>",
"      Joint effusion",
"     </li>",
"     <li>",
"      Loss of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduced active range of motion with preserved passive range of motion suggests soft tissue disorders such as bursitis, tendinitis, or muscle injury. If, on the other hand, both active and passive ranges of motion are decreased, then soft tissue contracture, synovitis, and a structural abnormality of the joint should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint examination is also helpful to confirm the absence of synovitis or the presence of bony enlargement or crepitus, as is typical of osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on general examination may point to a systemic condition. These findings include lymphadenopathy, parotid enlargement, oral ulcerations, heart murmurs, pericardial or pleural friction rubs, or fine inspiratory rales due to interstitial lung disease.",
"   </p>",
"   <p>",
"    Fever suggests a subset of infectious and rheumatic illnesses including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infectious arthritis",
"     </li>",
"     <li>",
"      Postinfectious or reactive arthritis (post-enteric infection, rheumatic fever)",
"     </li>",
"     <li>",
"      Systemic rheumatic disease, including Still&rsquo;s disease, vasculitis, or SLE",
"     </li>",
"     <li>",
"      Crystal-induced arthritis (gout and pseudogout)",
"     </li>",
"     <li>",
"      Other diseases such as cancer, sarcoidosis, and mucocutaneous disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional findings may suggest a specific disease process. Examples of such findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of subcutaneous nodules may be due to rheumatoid nodules or tophi.",
"     </li>",
"     <li>",
"      Skin lesions may suggest that the joint symptoms are due to psoriatic arthritis, SLE, viral infection, or Still&rsquo;s disease.",
"     </li>",
"     <li>",
"      Eye disease, including keratoconjunctivitis sicca, uveitis, conjunctivitis, and episcleritis, is also a feature of certain rheumatic illnesses.",
"     </li>",
"     <li>",
"      Concomitant axial pain or stiffness suggests the possibility of axial spondyloarthritis or another seronegative spondyloarthritis. As a result, spinal tenderness, deformity, and range of motion should always be ascertained in patients with polyarticular joint pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, soft tissue tender points characteristic of fibromyalgia are particularly important to identify in patients who have no objective abnormalities in the joints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .) However, joint tenderness may occur in some fibromyalgia patients, and patients with various types of polyarthritis, including RA, SLE, and Lyme disease, may have superimposed fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are not always necessary to make a diagnosis and, in fact, can be misleading. As an example, some patients with osteoarthritis may have abnormal results that actually reflect other unrelated conditions. In addition, in some patients with arthralgias and myalgias without physical findings, managing symptoms and carefully following the patient over several weeks may be more prudent than an initial battery of tests. Laboratory testing is also unnecessary when a mechanical or extraarticular problem has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the initial history and physical exam do not yield a diagnosis, however, some diagnostic testing may be indicated. Standard hematologic tests, urinalysis, and biochemical tests (renal and liver function) may help to identify patients with systemic illnesses. Other more specialized tests are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Erythrocyte sedimentation rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific indicators of inflammation, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are helpful in distinguishing between inflammatory and noninflammatory conditions. However, these tests are never diagnostic and may be abnormal in a vast array of infectious, malignant, rheumatic, and other diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/5\">",
"     5",
"    </a>",
"    ]. The CRP is sometimes a more reliable indicator of the acute phase response than the ESR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/6\">",
"     6",
"    </a>",
"    ], as the latter may be influenced by abnormal red blood cell morphology and a host of other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, there are numerous examples of the ESR yielding results that are not consistent with the actual rheumatologic process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with an inflammatory rheumatic disease have a normal ESR. In one series of patients with RA, for example, the ESR was persistently normal in 3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In noninflammatory arthritis, the ESR may be elevated because of another problem, such as renal failure, diabetes, hyperlipoproteinemia, dysproteinemia, or occult malignancy.",
"     </li>",
"     <li>",
"      The ESR may increase with age in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/8\">",
"       8",
"      </a>",
"      ]. This phenomenon may be the basis for apparent ESR elevations in some OA patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations, the ESR may provide confirmatory information when a certain diagnosis is favored based upon the history and physical findings. In an older patient with aching and stiffness in the hip and shoulder girdle areas, for example, the post-test probability of polymyalgia rheumatica increases if the ESR is markedly elevated. However, a normal ESR does not preclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody tests can identify exposure to potential pathogens (group A streptococcus, viruses such as parvovirus or hepatitis B and C, B. burgdorferi). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .) In addition, certain autoantibodies are associated with a limited group of illnesses and may add diagnostic specificity to a clinical suspicion of rheumatic disease (such as anti-native DNA or anti-Sm in SLE). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    .) These antibody tests should not be ordered routinely but should be reserved for cases in which there is a reasonable clinical suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/9\">",
"     9",
"    </a>",
"    ] (see below). The indiscriminate use of panels of these tests will result in a high frequency of false-positive results and in additional expensive and unnecessary testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antinuclear antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antinuclear antibody (ANA) test has high sensitivity but low specificity for SLE. Therefore, unless another cause is evident, it is generally appropriate to order an ANA in patients with polyarthritis since a negative test essentially rules out a diagnosis of SLE. A positive ANA may occur, however, in many rheumatic illnesses. Thus, a patient with few or no clinical features of SLE is unlikely to have the disease, even in the presence of a positive ANA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional information may help clarify the meaning of a positive ANA. First, the higher the ANA titer, the more likely that the patient has either SLE or another ANA associated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ]. Second, additional serologic tests, such as anti-dsDNA antibodies, may be diagnostic or at least may further limit the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rheumatoid factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factor should be ordered when RA is suspected because of signs or symptoms of inflammatory arthritis; however, the test has limited diagnostic value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/12\">",
"     12",
"    </a>",
"    ]. Approximately one-third of patients with RA remain seronegative throughout their course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, patients with other inflammatory or infectious diseases (such as SLE, infective endocarditis, vasculitis, viral infection) may have a positive test (",
"    <a class=\"graphic graphic_table graphicRef74945 \" href=\"mobipreview.htm?27/7/27772\">",
"     table 3",
"    </a>",
"    ). High rheumatoid factor titers have a better predictive value for the diagnosis of RA and may also predict poor outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antibodies to citrullinated peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA) are frequently found in patients with RA. ACPA, detected by anti-cyclic citrullinated peptide (anti-CCP) antibody testing, are more specific than RF for diagnosing RA and may predict erosive disease more effectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum uric acid concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum uric acid levels are usually elevated in gout, but, since asymptomatic hyperuricemia has a high prevalence in the general population, the test has little or no diagnostic value. In addition, normal uric acid levels are fairly common during an attack of gout, including in patients with polyarticular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Synovial fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid analysis may be diagnostic in patients with bacterial infections or crystal-induced synovitis. According to the American College of Rheumatology (ACR) clinical guidelines, this analysis should be performed in the febrile patient with an acute flare of established arthritis to rule out superimposed septic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ]. In other situations, its main value is to permit classification into an inflammatory or noninflammatory category. Thus, synovial fluid analysis should be performed if it is readily obtainable and if the diagnosis is uncertain after history, physical examination, and standard laboratory tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The white cell count, differential count, cultures, Gram stain, and polarized light microscopy are the most valuable studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Noninflammatory fluids generally have fewer than 2000 white blood",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    with fewer than 75 percent polymorphonuclear leukocytes (",
"    <a class=\"graphic graphic_table graphicRef76506 \" href=\"mobipreview.htm?31/4/31820\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/17\">",
"     17",
"    </a>",
"    ]. The ACR guidelines suggest that unexplained inflammatory fluid, particularly in a febrile patient, is assumed to be infected until proven otherwise by appropriate culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are expensive and are not required routinely in the evaluation of polyarticular pain. In situations in which they are useful, it is seldom necessary to obtain radiographs of all involved joints; those joints with the highest yield in the differential diagnosis should be chosen. As an example, if RA is the suspected diagnosis, erosions are best visualized in the wrist, hand, and foot.",
"   </p>",
"   <p>",
"    In acute conditions, radiographs usually lack diagnostic specificity and are generally not helpful for patients with new onset of RA, SLE, gout, tendinitis, or bursitis. In several acute settings, however, plain films may be useful. Chondrocalcinosis, for example, may be seen in calcium pyrophosphate deposition disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .) On the other hand, abnormalities of the sacroiliac (SI) joints are the earliest radiographic finding in ankylosing spondylitis and serve to point toward seronegative spondyloarthropathy as the cause of peripheral polyarthritis. Magnetic resonance imaging (MRI) is more sensitive than plain film radiography in detecting early SI joint abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain radiographs may also be helpful in the diagnosis of the following chronic conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In osteoarthritis, plain films can be used not only to confirm the diagnosis but also to assess the severity. Radiographs can, however, be normal in OA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In RA, marginal erosions in the joint can be diagnostic. MRI and ultrasound may be able to detect erosions before plain radiographs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic gout may also cause joint erosions, but these often have an &ldquo;overhanging edge&rdquo; suggestive of reparative changes that distinguishes them from erosions due to RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"       2",
"      </a>",
"      ]. Ultrasound may provide more specific information than conventional radiographs for the diagnosis of gout [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radionuclide scans and other imaging procedures are occasionally useful in identifying involvement of both relatively inaccessible joints (eg, hip, SI) and bone (eg, malignancy, infection, Paget disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TISSUE BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare instances, the correct diagnosis in a patient with polyarticular pain will depend upon a tissue biopsy. As an example, synovial biopsy may be useful in the diagnosis of tuberculosis, fungus, and sarcoid. Biopsy of other tissues may help establish the presence of Whipple's disease, vasculitis, and hemochromatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it may not be possible to make a definitive diagnosis at the time of a patient's initial presentation with polyarticular pain, some progress has been made in predicting the disease course for those with definite polyarthritis of recent onset. A combination of clinical, laboratory, and imaging data can help to differentiate patients likely to have self-limited disease from those likely to have persistent arthritis. A prediction model based upon data from 524 patients with early arthritis was more discriminating than the 1987 American College of Rheumatology classification criteria for rheumatoid arthritis in predicting disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/20\">",
"     20",
"    </a>",
"    ]. The following seven features were associated with persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosive disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration of symptoms prior to presentation",
"     </li>",
"     <li>",
"      Morning stiffness of an hour or more",
"     </li>",
"     <li>",
"      Arthritis in three or more joints",
"     </li>",
"     <li>",
"      Presence of pain on compression of the metatarsophalangeal joints",
"     </li>",
"     <li>",
"      Presence of serum rheumatoid factor",
"     </li>",
"     <li>",
"      Anti-CCP antibodies",
"     </li>",
"     <li>",
"      Erosions on initial radiographs of hands",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prediction model based upon these seven features needs to be validated on other cohorts of early arthritis patients before its usefulness can be accurately assessed, although subsequent studies have come to similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/10/30881?source=see_link\">",
"       \"Patient information: Arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the history and physical examination are used in concert with selected sequential laboratory and imaging studies, the cause of polyarticular joint pain can be identified in most cases. The ACR guidelines make the following general recommendations after completion of a thorough history and physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef79481 \" href=\"mobipreview.htm?14/50/15136\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of synovitis and symptoms greater than six weeks in duration, consider rheumatoid arthritis and other systemic rheumatic diseases (",
"      <a class=\"graphic graphic_table graphicRef74266 \" href=\"mobipreview.htm?31/60/32716\">",
"       table 1",
"      </a>",
"      ). A complete blood count (CBC), ESR, RF, anti-CCP, ANA, plasma creatinine concentration, and urinalysis should be obtained. Joint aspiration should be considered if an effusion is present and if the diagnosis is uncertain.",
"     </li>",
"     <li>",
"      In the presence of synovitis and symptoms less than six weeks in duration, initiate careful follow-up, obtain a CBC and liver function tests, and consider hepatitis B and C and parvovirus serologies (",
"      <a class=\"graphic graphic_table graphicRef73403 \" href=\"mobipreview.htm?15/52/16203\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the absence of synovitis, the physical examination finding of tender points suggests fibromyalgia or multiple sites of bursitis or tendinitis; further diagnostic testing is not needed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=see_link\">",
"       \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of synovitis and tender points, think of the remainder of the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef74266 \" href=\"mobipreview.htm?31/60/32716\">",
"       table 1",
"      </a>",
"      ) and consider liver function tests, hepatitis B and C serology, radiographs, and serum levels of TSH, calcium, albumin, and alkaline phosphatase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients presenting with polyarticular pain, the differential may be reduced to two or three reasonable possibilities. Further observation may be necessary to identify the correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19551292\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert S Pinals, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/1\">",
"      Pinals RS. Polyarthritis and fever. N Engl J Med 1994; 330:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/2\">",
"      Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/3\">",
"      El-Gabalawy HS, Duray P, Goldbach-Mansky R. Evaluating patients with arthritis of recent onset: studies in pathogenesis and prognosis. JAMA 2000; 284:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/4\">",
"      El-Gabalawy HS, Goldbach-Mansky R, Smith D 2nd, et al. Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum 1999; 42:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/5\">",
"      Sox HC Jr, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/6\">",
"      Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991; 34:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/7\">",
"      Pinals RS. Rheumatoid arthritis with a normal erythroycte sedimentation rate. J Rheumatol 1978; 5:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/8\">",
"      Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983; 286:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/9\">",
"      Sox HC Jr. Probability theory in the use of diagnostic tests. An introduction to critical study of the literature. Ann Intern Med 1986; 104:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/10\">",
"      Woolf SH, Kamerow DB. Testing for uncommon conditions. The heroic search for positive test results. Arch Intern Med 1990; 150:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/11\">",
"      Juby A, Johnston C, Davis P. Specificity, sensitivity and diagnostic predictive value of selected laboratory generated autoantibody profiles in patients with connective tissue diseases. J Rheumatol 1991; 18:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/12\">",
"      Shmerling RH, Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value. Arch Intern Med 1992; 152:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/13\">",
"      Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/14\">",
"      Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/15\">",
"      Hadler NM, Franck WA, Bress NM, Robinson DR. Acute polyarticular gout. Am J Med 1974; 56:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/16\">",
"      Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol 2009; 36:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/17\">",
"      Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA 1990; 264:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/18\">",
"      Baillet A, Gaujoux-Viala C, Mouterde G, et al. Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2011; 50:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/19\">",
"      Howard RG, Pillinger MH, Gyftopoulos S, et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken) 2011; 63:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/20\">",
"      Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/21\">",
"      Alves C, Luime JJ, van Zeben D, et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH). Ann Rheum Dis 2011; 70:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34039/abstract/22\">",
"      Ha YJ, Park YB, Son MK, et al. Predictive factors related to progression toward rheumatoid arthritis in Korean patients with undifferentiated arthritis. Rheumatol Int 2012; 32:1555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1821 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34039=[""].join("\n");
var outline_f33_15_34039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Musculoskeletal emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Joint symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other historical issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL SIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Joint examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Erythrocyte sedimentation rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibody tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antinuclear antibody",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rheumatoid factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antibodies to citrullinated peptides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum uric acid concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Synovial fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TISSUE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19551292\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1821|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?14/50/15136\" title=\"algorithm 1\">",
"      Evaluation of polyarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/60/32716\" title=\"table 1\">",
"      Causes polyarticular joint pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/52/16203\" title=\"table 2\">",
"      Viruses and polyarthralgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/7/27772\" title=\"table 3\">",
"      RF in nonrheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/4/31820\" title=\"table 4\">",
"      Categories of synovial fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/10/30881?source=related_link\">",
"      Patient information: Arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34040="Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)";
var content_f33_15_34040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Fernando C Fervenza, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Sanjeev Sethi, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Mark H Wener, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34040/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/15/34040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H898864\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential mixed cryoglobulinemic vasculitis was the traditional term for idiopathic vasculitis caused by the deposition of circulating cryoglobulins that contain both a polyclonal IgG and an IgM rheumatoid factor directed against the IgG, which are also called mixed cryoglobulins. In most patients, this disorder is associated with chronic hepatitis C virus (HCV) infection.",
"   </p>",
"   <p>",
"    <br/>",
"    A more accurate term for this type of vasculitis is the mixed cryoglobulinemia syndrome, which refers to primary or idiopathic cryoglobulinemia as well as cryoglobulinemia associated with autoimmune diseases, malignancy, or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/1\">",
"     1",
"    </a>",
"    ]. The mixed cryoglobulinemia syndrome can be caused by either type II or type III cryoglobulins, the characteristics of which are defined in the next section. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Types of cryoglobulins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The etiology, clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome will be reviewed here. The treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     TYPES OF CRYOGLOBULINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoglobulins are immunoglobulins that precipitate in the cold and dissolve on rewarming. The biochemical characteristics that promote cryoprecipitation are not well understood. Cryoglobulins that contain more than one immunoglobulin component are called",
"    <strong>",
"     mixed",
"    </strong>",
"    cryoglobulins.",
"   </p>",
"   <p>",
"    Three different immunochemical types of cryoglobulins have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Classification'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I cryoglobulinemia, in which the only immunoglobulin component of the cryoglobulin is a monoclonal immunoglobulin, is most often due to underlying multiple myeloma or Waldenstr&ouml;m&rsquo;s macroglobulinemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/4\">",
"       4",
"      </a>",
"      ]. Type I cryoglobulins are usually IgM or IgG, but IgA and serum monoclonal free light chain cryoglobulins have been reported. Patients with type I cryoglobulins are usually asymptomatic, but the cryoglobulins may precipitate at room temperature which can produce symptoms similar to those of the mixed cryoglobulinemia syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Type II mixed cryoglobulinemia, in which the cryoglobulin contains both a polyclonal IgG and a monoclonal IgM rheumatoid factor directed against the IgG is most often due to chronic infection with hepatitis C virus (HCV) although infection with hepatitis B virus and Epstein-Barr virus has been implicated in some patients.",
"     </li>",
"     <li>",
"      Type III mixed cryoglobulinemia, in both the IgG and the IgM rheumatoid factor are polyclonal. This disorder is often seen in chronic inflammatory and autoimmune diseases (such as systemic lupus erythematosus and Sj&ouml;gren&rsquo;s syndrome), lymphoproliferative malignancies, and, in as many as one-half of cases, HCV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/6-9\">",
"       6-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative frequency of the three types of cryoglobulins was evaluated in a multicenter study in which immunochemical classification was performed in 694 patients with cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/9\">",
"     9",
"    </a>",
"    ]. Type I was present in 6 percent, type II in 62 percent, and type III in 32 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101131084\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of mixed cryoglobulinemia syndrome is chronic hepatitis C virus infection. Other causes include chronic hepatitis B virus infection, other causes of chronic liver disease, and HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the association of hepatitis C virus (HCV) infection with mixed cryoglobulinemia syndrome includes the following observations:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three studies with a total of 101 patients with mixed cryoglobulinemia syndrome found that 95 (95 percent) had one or more of the following signs of HCV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/6,7,10\">",
"       6,7,10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Circulating anti-HCV antibodies",
"     </li>",
"     <li>",
"      HCV RNA in the plasma and enriched in the cryoprecipitate",
"     </li>",
"     <li>",
"      The presence of polyclonal IgG anti-HCV antibodies within the cryoprecipitate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A larger study of 654 patients with mixed cryoglobulinemia syndrome found that 80 percent had antibodies to HCV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings support an etiologic role for HCV in most patients with mixed cryoglobulinemia syndrome. Although hepatomegaly and chronic liver disease are common in these patients, some do not have elevated serum aminotransferase levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, there may be little or no clinical evidence of active hepatitis at the time of presentation.",
"   </p>",
"   <p>",
"    A separate issue is that most HCV-infected patients who have circulating cryoglobulins do",
"    <strong>",
"     not",
"    </strong>",
"    develop vasculitis. This was illustrated in a study of 226 patients with chronic liver disease, 127 of whom had HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixty-nine HCV-infected patients (54 percent) had circulating cryoglobulins, frequently with anti-HCV antibodies and HCV RNA concentrated in the cryoprecipitates (",
"      <a class=\"graphic graphic_figure graphicRef80075 \" href=\"mobipreview.htm?29/19/30013\">",
"       figure 1",
"      </a>",
"      ). Type II cryoglobulins were present in 22 (17 percent) and type III cryoglobulins were present in 47 (37 percent). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Types of cryoglobulins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of circulating cryoglobulins was higher with increasing apparent duration of disease (9.8 versus 5.3 years) and the presence of cirrhosis.",
"     </li>",
"     <li>",
"      Eighteen (26 percent) of the patients with circulating cryoglobulins had clinical symptoms compatible with mixed cryoglobulinemia syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, testing for serum cryoglobulins should be performed in patients with HCV infection who have arthralgias or arthritis, evidence of otherwise unexplained renal disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasculitic erythematous skin lesions that are typically located on the lower extremities. Similarly, HCV infection should be sought in all patients with a diagnosis of mixed cryoglobulinemia syndrome. (See",
"    <a class=\"local\" href=\"#H160897078\">",
"     'Role of HCV infection'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H64200389\">",
"     'Testing for cryoglobulins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In some parts of northern Europe, such as the Netherlands, there is a very low prevalence of HCV infection and HCV is not found in patients with mixed cryoglobulinemia syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HBV and other causes of chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the series of 226 patients with chronic liver disease, which included the 127 patients described in the preceding section, chronic HBV infection was present in 40 patients; circulating cryoglobulins were present in 15 percent (compared with 4 percent in controls) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/11\">",
"     11",
"    </a>",
"    ]. HBV-associated cryoglobulinemic vasculitis has been described in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The remaining 59 patients had other hepatic diseases, including autoimmune hepatitis and primary biliary cirrhosis. Circulating cryoglobulins were present in 19 of these patients (32 percent). The prevalence of cryoglobulinemia was higher in patients with increasing duration of disease and the presence of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of mixed cryoglobulinemia syndrome are due to HIV infection. This relationship was illustrated in a consecutive, unselected series of 89 HIV-1-infected patients from Greece in whom mixed cryoglobulinemia was detected in 24 (27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/15\">",
"     15",
"    </a>",
"    ]. Antibodies to HIV-1 were detected in all of the cryoprecipitates, and HIV-1 RNA sequences were detected in all but one of the cryoprecipitates. Nine of these patients had symptoms compatible with mixed cryoglobulinemia syndrome (eg, palpable purpura, arthralgias, and mononeuritis multiplex). Only 6 of the 24 patients with circulating cryoglobulins were infected with hepatitis C virus (HCV), and only three of these patients had HCV RNA sequences in the cryoprecipitate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed cryoglobulinemia syndrome is mediated by the deposition of antigen-antibody complexes in capillaries and small arterioles, and occasionally also in small arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In skin biopsies, the hallmark of mixed cryoglobulinemia syndrome is small vessel leukocytoclastic vasculitis. The inflammation leads to destruction of the vessel wall with evidence of polymorphonuclear leukocyte nuclear debris (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vasculitis is associated with deposition of immunoglobulins and complement in the vessel wall, and occasionally with precipitated cryoproteins within the vessel lumen. Thus, small vessel immune complex vasculitis plays the major role, and localized hyperviscosity due to cryoprecipitation of the proteins within the lumen may contribute. Serum levels of complement C4 are typically (but not always) low when patients have symptomatic mixed cryoglobulinemia syndrome, reflecting complement consumption via the classical, immune complexed-mediated activation of the complement cascade.",
"   </p>",
"   <p>",
"    The pathologic findings in patients with renal disease are presented below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Renal disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160897078\">",
"    <span class=\"h2\">",
"     Role of HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hepatitis C virus (HCV) infection, the immune complex consists of HCV, anti-HCV IgG, and IgM anti-IgG (rheumatoid factor). It is unclear why cryoglobulins are produced and why some antigens trigger this process. The HCV virion may serve as the inciting agent, since it has been found in high concentrations in the cryoprecipitate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increased production, decreased clearance of circulating immune complexes due to hepatic dysfunction may promote cryoglobulin accumulation in the circulation and subsequent tissue deposition. This is suggested by the association between circulating cryoglobulins and prolonged liver disease and cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'HCV infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another possible causal link between chronic HCV infection and mixed cryoglobulinemia syndrome is the finding that chronic HCV infection is associated with the presence of rheumatoid factor, and HCV-infected lymphocytes occasionally secrete immunoglobulins with rheumatoid factor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/16\">",
"     16",
"    </a>",
"    ]. The monoclonal rheumatoid factors associated with HCV-related cryoglobulinemia are encoded by a limited set of immunoglobulin heavy and light chain genes, which are sometimes also seen in patients with HCV infection who do not have cryoglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H270270944\">",
"    <span class=\"h2\">",
"     Major manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations of mixed cryoglobulinemia syndrome include palpable purpura (which is a major finding suggesting some form of small vessel vasculitis) (",
"    <a class=\"graphic graphic_picture graphicRef78697 \" href=\"mobipreview.htm?9/36/9794\">",
"     picture 1",
"    </a>",
"    ), renal disease, arthralgias or arthritis, nonspecific systemic symptoms including weakness, peripheral neuropathy, and hypocomplementemia (with the fall in C4 levels often being most prominent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/2,3,7-9,18,19\">",
"     2,3,7-9,18,19",
"    </a>",
"    ]. Patients may present with various combinations of these features and different manifestations may predominate at different times in an individual patient.",
"   </p>",
"   <p>",
"    A review of 231 patients with mixed cryoglobulinemia syndrome followed in an Italian rheumatology clinic found the following clinical findings at presentation and during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common clinical features at presentation were purpura (81 percent, with skin ulcers in 11 percent), weakness and fatigue (80 percent), arthralgia (72 percent), and frank arthritis (8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/18\">",
"       18",
"      </a>",
"      ]. The clinical triad of purpura, weakness, and arthralgia (&ldquo;Meltzer&rsquo;s triad&rdquo;) was present early in the course in almost 80 percent of patients.",
"     </li>",
"     <li>",
"      Peripheral neuropathy was present in 58 percent, typically with a mild peripheral sensorimotor pattern. A minority of these patients progressed to more severe neuropathy.",
"     </li>",
"     <li>",
"      Renal involvement was present in 20 percent, and eventually developed in 30 percent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mild to moderate liver involvement was present in 58 percent, and eventually developed in 77 percent, including some patients who advanced to cirrhosis.",
"     </li>",
"     <li>",
"      Raynaud&rsquo;s phenomenon was present in 36 percent, and sicca symptoms were present in 29 percent.",
"     </li>",
"     <li>",
"      Laboratory testing revealed type II cryoglobulinemia in 62 percent and type III cryoglobulinemia in 38 percent. Rheumatoid factor was found in all patients and most had hypocomplementemia, typically with very low C4 levels. Evidence of hepatitis C virus infection was found in 92 percent of patients, and hepatitis B surface antigen was present in 9 percent.",
"     </li>",
"     <li>",
"      The clinical features were similar in patients with type II and type III mixed cryoglobulinemia syndrome, except for more frequent sicca symptoms in the latter group.",
"     </li>",
"     <li>",
"      The long-term prognosis was evaluated but this issue is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"       \"Treatment of the mixed cryoglobulinemia syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of renal disease, typically glomerulonephritis, is apparent at presentation in about 20 percent of patients with mixed cryoglobulinemia syndrome, with an additional 10 to 30 percent developing renal disease during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/8,9,18,20-22\">",
"     8,9,18,20-22",
"    </a>",
"    ]. On average, renal disease is detected approximately 2.5 years after disease onset with a range of 0 to 28 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal disease associated with hepatitis C virus infection\", section on 'Mixed (IgG/IgM) cryoglobulinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation of the renal disease is variable. The following renal presentations were noted in a review of 146 patients with HCV-related mixed cryoglobulinemic syndrome with glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microscopic hematuria and subnephrotic proteinuria with or without chronic renal insufficiency &ndash; 41 percent",
"     </li>",
"     <li>",
"      Nephrotic syndrome with or without chronic renal insufficiency &ndash; 22 percent",
"     </li>",
"     <li>",
"      Acute glomerulonephritis &ndash; 14 percent",
"     </li>",
"     <li>",
"      Chronic kidney disease without significant urinalysis abnormalities &ndash; 13 percent",
"     </li>",
"     <li>",
"      Acute renal failure &ndash; 9 percent",
"     </li>",
"     <li>",
"      Hypertension was present in approximately 65 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The renal presentations were similar in patients with type II and type III mixed cryoglobulinemia syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314618617\">",
"    <span class=\"h4\">",
"     Findings on renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of the kidney reveals a membranoproliferative glomerulonephritis in over 80 percent of patients, with both thickening of the glomerular basement membrane and cellular proliferation (",
"    <a class=\"graphic graphic_picture graphicRef71702 \" href=\"mobipreview.htm?28/57/29593\">",
"     picture 2",
"    </a>",
"    ), including a far greater influx of circulating macrophages than seen in other forms of proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three other histologic findings are more specific for cryoglobulin-induced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraluminal thrombi composed of precipitated cryoglobulins on light microscopy (",
"      <a class=\"graphic graphic_picture graphicRef50680 \" href=\"mobipreview.htm?11/15/11513\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diffuse IgM deposition in the capillary loops on immunofluorescence microscopy (",
"      <a class=\"graphic graphic_picture graphicRef60046 \" href=\"mobipreview.htm?39/26/40367\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Subendothelial deposits on electron microscopy (",
"      <a class=\"graphic graphic_picture graphicRef69200 \" href=\"mobipreview.htm?22/59/23481\">",
"       picture 5",
"      </a>",
"      ) that often have a clear substructure with a characteristic \"fingerprint\" pattern of cryoprecipitates (",
"      <a class=\"graphic graphic_picture graphicRef81450 \" href=\"mobipreview.htm?35/5/35929\">",
"       picture 6",
"      </a>",
"      ). Subepithelial deposits are uncommon, since the cryoglobulins are too large to pass through the glomerular basement membrane and enter the subepithelial space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in experimental animals suggest that the different lesions may be caused by different types of cryoglobulins. In particular, the physicochemical characteristics of a cryoglobulin, determined in part by its variable region, may be an important determinant of whether it produces no renal disease, intraluminal thrombi, or subendothelial deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HCV-containing immune complexes may play a direct role in the pathogenesis of the renal disease. In one report, monoclonal antibodies directed against specific HCV antigens were used to detect HCV in the glomeruli by immunohistochemistry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/25\">",
"     25",
"    </a>",
"    ]. HCV antigens were detected along the glomerular capillary walls and in the mesangium in 8 of 12 patients with HCV-positive mixed cryoglobulinemia syndrome but in none of eight controls with HCV RNA-negative and anti-HCV negative mixed cryoglobulinemia syndrome or membranoproliferative glomerulonephritis.",
"   </p>",
"   <p>",
"    The presence of renal disease is a major factor in determining the long-term prognosis of patients with mixed cryoglobulinemia syndrome. Risk factors for progression of the renal disease are similar to those noted in other forms of glomerular disease: an elevated serum creatinine; higher rates of proteinuria; and older age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64202274\">",
"    <span class=\"h2\">",
"     Rare manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the more common findings in mixed cryoglobulinemia syndrome, there are several rare manifestations. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically apparent central nervous system dysfunction is rarely noted, but deficits in attention and higher cognitive function as well as magnetic resonance imaging abnormalities of uncertain significance may be present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary involvement may be present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/27-29\">",
"       27-29",
"      </a>",
"      ], but significant clinical manifestations are only rarely reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of mixed cryoglobulinemia syndrome is typically made from the history, typical manifestations of the disease such as purpura and hypocomplementemia, and the presence of cryoglobulins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]. Positive serologic testing for hepatitis C virus supports the diagnosis of HCV-related cryoglobulinemia. The presence of elevated rheumatoid factor titers in patients with arthritis or purpura and hypocomplementemia but without clinical evidence for rheumatoid arthritis should raise the possibility of mixed cryoglobulinemia syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64200389\">",
"    <span class=\"h2\">",
"     Testing for cryoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method used to test for and quantify cryoglobulins is discussed in detail separately. Summarized briefly, 10 to 20 mL of blood are drawn into syringes or collection tubes that have been",
"    <strong>",
"     prewarmed to 37&ordm;C without anticoagulants",
"    </strong>",
"    , since anticoagulants can produce false positive results due to cryofibrinogen or heparin-precipitable complexes. False negative results can be seen if this protocol is not followed. In cases in which cryoglobulinemia is suspected but initial results are negative consideration should be given to drawing a new specimen which is kept warm and handled by the clinical laboratory to prevent cryoprecipitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Detection and analysis of cryoglobulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with mixed cryoglobulinemia, the cryocrit is generally between 2 and 7 percent in type II and 1 and 3 percent in type III. The cryocrit in individuals without cryoglobulinemia is close to zero and a cryocrit over 0.5 to 1 percent or cryoglobulin concentration above 2 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is considered clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/2,34,35\">",
"     2,34,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Types of cryoglobulins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a poor correlation between the cryocrit and clinical manifestations of mixed cryoglobulinemia syndrome. In addition, many patients with chronic hepatitis C virus (HCV) infection have mixed cryoglobulinemia",
"    <strong>",
"     without",
"    </strong>",
"    the clinical syndrome of mixed cryoglobulinemia. This was illustrated in a study of 1083 unselected patients with chronic HCV infection in which 40 percent had low concentrations of serum cryoglobulins, which were type II in 65 percent and type III in 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/36\">",
"     36",
"    </a>",
"    ]. Among the patients with cryoglobulinemia, only 2.1 percent had vasculitis and 2.5 percent had purpura.",
"   </p>",
"   <p>",
"    As many as 30 to 40 percent of the patients with type II and occasional patients with type III mixed cryoglobulinemia do",
"    <strong>",
"     not",
"    </strong>",
"    have detectable circulating cryoglobulins at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/21\">",
"     21",
"    </a>",
"    ]. This may be due, in part, to technical issues. In addition, some patients who present with renal disease do not have detectable cryoglobulins or common manifestations of mixed cryoglobulinemia syndrome such as purpura and arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Laboratory tests that suggest the presence of a cryoglobulin are a positive rheumatoid factor together with hypocomplementemia with low C4 levels, particularly in patients with membranoproliferative glomerulonephritis on renal biopsy. In some patients, immune deposits with ultrastructural features compatible with cryoglobulins can be detected on biopsy of affected tissue, such as the kidney or skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H314618617\">",
"     'Findings on renal biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H314617827\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of a purpuric skin lesion can often confirm that leukocytoclastic vasculitis is present, and occasionally cryoglobulins can be identified within the skin blood vessel lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy can be performed on the skin biopsy, to confirm the presence of immunoglobulin and complement in vessel walls.",
"   </p>",
"   <p>",
"    Renal biopsy should be reserved for patients with evidence of renal disease, such as renal insufficiency, hematuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Renal disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Testing for HCV, HBV, and HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible infection with hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV infection should be investigated in",
"    <strong>",
"     all",
"    </strong>",
"    patients with mixed cryoglobulinemia syndrome given the etiologic relationship described above. (See",
"    <a class=\"local\" href=\"#H101131084\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    HCV RNA has been found in the liver and in peripheral blood mononuclear cells of patients with chronic liver disease in the absence of both HCV RNA and anti-HCV antibodies in the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/39\">",
"     39",
"    </a>",
"    ]. Rarely, whole blood or the cryoprecipitate may test positive for HCV when routinely handled serum does not, because of removal of virtually all of the HCV virion from serum or plasma into the cryoprecipitate or cellular phase of blood.",
"   </p>",
"   <p>",
"    Issues related to testing for these infections are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spurious leukocytosis and thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mixed cryoglobulinemia syndrome may have a temperature-dependent increase in the apparent leukocyte and platelet counts when blood samples are tested at temperatures of 30&ordm;C or less. This can result in white blood cell counts as high as",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles, which may be counted as white blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelets in automated cell counters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34040/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This effect is increased if the sample is allowed to cool to lower temperatures and disappears if the sample is kept at body temperature. However, many hematology instruments do not allow temperature-controlled analyses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Spurious thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mixed cryoglobulinemia syndrome is a systemic disease caused by the deposition of antigen-antibody complexes (immune complexes) in small and medium-sized arteries. Type II mixed cryoglobulins contain both a polyclonal IgG and a monoclonal IgM rheumatoid factor directed against the IgG. Type III mixed cryoglobulins typically contain polyclonal IgM rheumatoid factor and polyclonal IgG. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Types of cryoglobulins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mixed cryoglobulinemia syndrome is most often due to chronic HCV infection. It is much less frequently associated with hepatitis B virus (HBV), HIV, or Epstein-Barr infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'HCV infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited data suggest that the prevalence of cryoglobulinemia is approximately 50 percent among patients with chronic HCV infection, but less than one-third of those who have circulating cryoglobulins have the mixed cryoglobulinemia syndrome with vasculitis. The prevalence of cryoglobulinemia increases with duration of disease and the presence of cirrhosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical manifestations of the mixed cryoglobulinemia syndrome include palpable purpura, arthralgias, lymphadenopathy, hepatosplenomegaly, peripheral neuropathy, and hypocomplementemia (with the fall in C4 levels often being the prominent abnormality among complement tests). Patients with cryoglobulinemia may have little or no clinical evidence of active hepatitis at the time of presentation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'HCV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal disease occurs in 20 to 60 percent of patients with the mixed cryoglobulinemia syndrome and is most often observed two to three years after the onset of cryoglobulinemia. Manifestations of renal disease include hematuria with or without renal insufficiency, nephrotic syndrome, acute nephritis, chronic kidney disease without significant renal abnormalities, and acute renal failure. The mortality of patients with renal disease as a manifestation of mixed cryoglobulinemia syndrome is substantially higher than those without renal disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of mixed cryoglobulinemia syndrome is made from the history, the presence of skin purpura and other manifestations, low complement levels, and demonstration of circulating cryoglobulins. HCV, HBV and HIV infection should be sought in all patients diagnosed with mixed cryoglobulinemia syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy of a purpuric skin lesion can often confirm that the cryoglobulins are responsible for the patient's signs and symptoms. Renal biopsy should be reserved for patients with evidence of renal disease, such as renal insufficiency, hematuria or proteinuria. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/1\">",
"      Meltzer M, Franklin EC. Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/2\">",
"      Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/3\">",
"      D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989; 35:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/4\">",
"      Paueksakon P, Revelo MP, Horn RG, et al. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003; 42:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/5\">",
"      Letendre L, Kyle RA. Monoclonal cryoglobulinemia with high thermal insolubility. Mayo Clin Proc 1982; 57:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/6\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/7\">",
"      Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/8\">",
"      Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/9\">",
"      Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/10\">",
"      Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/11\">",
"      Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/12\">",
"      Tervaert JW, Van Paassen P, Damoiseaux J. Type II cryoglobulinemia is not associated with hepatitis C infection: the Dutch experience. Ann N Y Acad Sci 2007; 1107:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/13\">",
"      Kawakami T, Ooka S, Mizoguchi M, et al. Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med 2008; 149:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/14\">",
"      Enomoto M, Nakanishi T, Nakamishi T, et al. Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med 2008; 149:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/15\">",
"      Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Ann Intern Med 1999; 130:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/16\">",
"      Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160:3594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/17\">",
"      Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010; 62:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/18\">",
"      Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/19\">",
"      Iannuzzella F, Vaglio A, Garini G. Management of hepatitis C virus-related mixed cryoglobulinemia. Am J Med 2010; 123:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/20\">",
"      Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/21\">",
"      Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/22\">",
"      Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/23\">",
"      Sinico RA, Winearls CG, Sabadini E, et al. Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis. Kidney Int 1988; 34:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/24\">",
"      Fulpius T, Berney T, Lemoine R, et al. Glomerulopathy induced by IgG3 anti-trinitrophenyl monoclonal cryoglobulins derived from non-autoimmune mice. Kidney Int 1994; 45:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/25\">",
"      Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997; 25:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/26\">",
"      Casato M, Saadoun D, Marchetti A, et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 2005; 32:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/27\">",
"      Nash JW, Ross P Jr, Neil Crowson A, et al. The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. Am J Clin Pathol 2003; 119:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/28\">",
"      Manganelli P, Salaffi F, Subiaco S, et al. Bronchoalveolar lavage in mixed cryoglobulinaemia associated with hepatitis C virus. Br J Rheumatol 1996; 35:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/29\">",
"      Viegi G, Fornai E, Ferri C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol 1989; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/30\">",
"      Lee LN, Lo SC, Lau HP, et al. Hepatitis C-associated cryoglobulinaemia presenting with refractory hypertensive crisis and acute pulmonary oedema. Med J Aust 2005; 182:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/31\">",
"      Suzuki R, Morita H, Komukai D, et al. Mixed cryoglobulinemia due to chronic hepatitis C with severe pulmonary involvement. Intern Med 2003; 42:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/32\">",
"      Jara LJ, Vera-Lastra O, Calleja MC. Pulmonary-renal vasculitic disorders: differential diagnosis and management. Curr Rheumatol Rep 2003; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/33\">",
"      Frankel AH, Singer DR, Winearls CG, et al. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/34\">",
"      Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998; 57:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/35\">",
"      Della Rossa A, Tavoni A, D'Ascanio A, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/36\">",
"      Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/37\">",
"      Berliner S, Weinberger A, Ben-Bassat M, et al. Small skin blood vessel occlusions by cryoglobulin aggregates in ulcerative lesions in IgM-IgG cryoglobulinemia. J Cutan Pathol 1982; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/38\">",
"      Rongioletti F, Patterson JW, Rebora A. The histological and pathogenetic spectrum of cutaneous disease in monoclonal gammopathies. J Cutan Pathol 2008; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/39\">",
"      Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 2010; 39:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/40\">",
"      Zandecki M, Dupriez B, Fenaux P, et al. Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia. Nouv Rev Fr Hematol 1989; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34040/abstract/41\">",
"      Hutchinson CV, Stelfox P, Rees-Unwin KS. Needle-like cryoglobulin crystals presenting as spurious thrombocytosis. Br J Haematol 2006; 135:280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3062 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34040=[""].join("\n");
var outline_f33_15_34040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H898864\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      TYPES OF CRYOGLOBULINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101131084\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HBV and other causes of chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160897078\">",
"      Role of HCV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H270270944\">",
"      Major manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H314618617\">",
"      Findings on renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64202274\">",
"      Rare manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64200389\">",
"      Testing for cryoglobulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H314617827\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Testing for HCV, HBV, and HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spurious leukocytosis and thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3062|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/19/30013\" title=\"figure 1\">",
"      Cryos in chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3062|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/36/9794\" title=\"picture 1\">",
"      Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/57/29593\" title=\"picture 2\">",
"      MPGN in mixed cryo Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/15/11513\" title=\"picture 3\">",
"      Capillary microthrombi mixed cryo Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/26/40367\" title=\"picture 4\">",
"      IgM deposits in mixed cryo IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/59/23481\" title=\"picture 5\">",
"      Subendothelial deposits in mixed cryo EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/5/35929\" title=\"picture 6\">",
"      Fingerprint pattern in mixed cryo EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34041="Pre-exposure prophylaxis against HIV infection";
var content_f33_15_34041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pre-exposure prophylaxis against HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     Kenneth H Mayer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34041/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/15/34041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7740404\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of an effective HIV vaccine, up to two million new HIV infections still occur yearly worldwide. Pre-exposure prophylaxis with antiretroviral medications is a concept that has been widely recognized as a potential way to prevent new infections among those at risk.",
"   </p>",
"   <p>",
"    This topic will review the rationale and potential pitfalls of pre-exposure prophylaxis for nonoccupational exposures to HIV infection.",
"   </p>",
"   <p>",
"    Postexposure prophylaxis for HIV infection, male circumcision, and the prevention of other sexually transmitted diseases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740428\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis against HIV infection after possible sexual exposure has been in clinical practice for several years, although the data supporting its efficacy are limited to animal model studies and retrospective case control studies in humans. Barriers to the implementation of postexposure prophylaxis include the need for rapid evaluation and prompt initiation of medications. Furthermore, individuals may not promptly seek postexposure prophylaxis for HIV because they incorrectly assume their partner was HIV-uninfected. In addition, the window of opportunity to halt transmission through host defenses is very limited because submucosal viral replication occurs within hours of exposure. Finally, even among those who agree to take postexposure prophylaxis, there is a high rate of noncompletion of the recommended 28-day course of triple therapy due to medication side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A universal approach utilizing HIV prophylaxis for all high-risk sexual exposures could potentially reduce HIV acquisition. Data from randomized trials, as well as growing observational and modeling data suggest that treatment of large populations of patients with chronic HIV infection leads to the ancillary benefit of decreased transmission, presumably by decreasing genital tract HIV concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There are also examples of other infectious diseases where chemoprophylaxis is given prior to exposure to prevent acquisition of infection, such as malaria. However, prophylaxis for malaria requires only a circumscribed period of days or months of drug exposure, whereas chemoprophylaxis for the prevention of HIV could potentially span years. Hence, the optimal use of antiretroviral drugs for pre-exposure chemoprophylaxis is not yet fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740420\">",
"    <span class=\"h1\">",
"     PROPOSED CANDIDATE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal candidate drug or drugs for preventive strategies would have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excellent tolerability",
"     </li>",
"     <li>",
"      Low toxicity",
"     </li>",
"     <li>",
"      Pharmacokinetics allowing once-daily dosing",
"     </li>",
"     <li>",
"      A high genetic barrier of resistance",
"     </li>",
"     <li>",
"      Adequate drug concentrations in blood, rectal mucosa, and genital fluids",
"     </li>",
"     <li>",
"      Low cost",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tolerability is a key issue in prophylaxis, since adverse effects may negatively impact adherence and completion of prophylaxis. A medication with a high &ldquo;genetic barrier&rdquo; to resistance requires multiple viral mutations before drug activity is compromised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link&amp;anchor=H13#H13\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Genetic barrier to resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2296983\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;One particular antiretroviral medication combination that has engendered great interest is that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    , coformulated as Truvada. Both drugs have long intracellular and plasma half-lives and are well tolerated. The plasma and intracellular half-lives of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and tenofovir-diphosphate (the active moiety) are 17 and 150 hours, respectively, while the plasma and intracellular half-lives of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and emtricitabine-triphosphate are 10 and 39 hours, respectively. These data provide the pharmacokinetic basis for once-daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/4\">",
"     4",
"    </a>",
"    ]. Some data from human and animal studies suggest that less frequent dosing of these agents may be just as efficacious due to these favorable pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=see_link\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7740412\">",
"     'Animal data'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2296990\">",
"    <span class=\"h2\">",
"     Genital tract penetration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) achieve higher concentrations in genital tract secretions than in blood, which might make them particularly effective in decreasing sexual transmission of HIV. In contrast, protease inhibitors are highly protein bound and achieve lower concentrations in the genital tract than NRTIs and NNRTIs.",
"   </p>",
"   <p>",
"    NRTIs with good penetration into the female genital tract include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/6\">",
"     6",
"    </a>",
"    ]. Another drug that has engendered interest for pre-exposure prophylaxis is the CCR5 inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , which is generally well tolerated and has high penetration into the genital tract and rectal compartments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2296997\">",
"    <span class=\"h2\">",
"     HIV drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An area of concern regarding pre-exposure prophylaxis is the development of drug resistance if an at-risk person uses one or two drugs, and becomes subsequently infected with HIV, either because of exposure to a resistant strain, or because of suboptimal adherence. (See",
"    <a class=\"local\" href=\"#H7740786\">",
"     'Drug resistance in clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , a competing concern is the relatively low genetic barrier to resistance that could render them ineffective against drug-resistant HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2296943\">",
"    <span class=\"h1\">",
"     HOW MANY DRUGS ARE NEEDED FOR PRE-EXPOSURE PROPHYLAXIS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal number of drugs needed for chemoprophylaxis of HIV infection is unknown.",
"   </p>",
"   <p>",
"    The advantages of using one drug include simplicity, lower risk of drug toxicity, and cost. The potential disadvantage of using one drug includes the risk of drug resistance if HIV infection should occur, despite prophylaxis. Ideally, if two drugs are used for pre-exposure prophylaxis, they should work at different stages of the viral life cycle and have a high genetic barrier to infection to decrease the risk of drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297123\">",
"    <span class=\"h1\">",
"     ROUTE OF DRUG EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal route of drug exposure is unknown.",
"   </p>",
"   <p>",
"    It will be important to determine which route of administration is most effective for each specific population because local anatomy (vaginal versus rectal mucosa) and tissue pharmacology may determine the relative advantages of one approach over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297164\">",
"    <span class=\"h1\">",
"     WHEN SHOULD PRE-EXPOSURE PROPHYLAXIS BE OFFERED?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing trials will address whether pre-exposure prophylaxis should be given on a daily, intermittent, or coitally-associated basis. Pericoital prophylaxis has been found to be highly efficacious in an animal model. (See",
"    <a class=\"local\" href=\"#H7740412\">",
"     'Animal data'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740412\">",
"    <span class=\"h1\">",
"     ANIMAL DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proof of concept model in macaques, using related viruses (simian immunodeficiency virus or a simian-human immunodeficiency virus hybrid) demonstrated protection against retroviral infection when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    was given 48 hours prior to exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/9\">",
"     9",
"    </a>",
"    ]. Since the publication of this landmark article in 1995, there has been intense interest in the efficacy and safety of such an approach to prevent HIV transmission.",
"   </p>",
"   <p>",
"    Numerous animal model studies have demonstrated that ART administered parenterally, orally, or topically before or just after retrovirus challenge is protective against HIV acquisition. The protective activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    has been demonstrated in mice transplanted with human immune cells and in nonhuman primates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven of eight humanized mice who were inoculated vaginally with HIV were infected compared with none of the five mice who received pre-exposure prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a macaque model, the risk of acquiring HIV infection after rectal exposure was fourfold lower in animals receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      alone and eightfold lower in animals receiving both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and emtricitabine compared with control animals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies in macaques have evaluated whether intermittent dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    may be effective in preventing rectal transmission of a simian retrovirus, as a surrogate for HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/12\">",
"     12",
"    </a>",
"    ]. In one study, administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    to macaques on days 1, 3 or 7 before rectal exposure to SIV, followed by a second dose two hours after exposure, had an efficacy rate of about 85 percent. However, no protection was seen if the first dose was delayed until 24 hours after exposure, underscoring the importance of blocking initial replication in the genital mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49825196\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740706\">",
"    <span class=\"h2\">",
"     Clinical data in men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data in MSM suggest that pre-exposure prophylaxis may be safe and effective, although many questions remain regarding optimal strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184114\">",
"    <span class=\"h3\">",
"     Pre-exposure Prophylaxis Initiative",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multinational trial called Pre-exposure Prophylaxis Initiative (iPrEX), which was conducted in six countries in four different continents, 2470 HIV-seronegative men and 29 transgender women were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    combination prophylaxis or placebo once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. All participants received HIV testing, risk reduction counseling, condoms, and management of sexually transmitted diseases (STDs) at enrollment and throughout the trial. The participants were followed for a median of 1.2 years; pill counts and medication history were taken serially throughout the trial. The following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One hundred patients became infected during follow-up (36 in the intervention arm and 64 in the placebo group) consistent with a 44 percent reduction in the incidence of HIV with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (95% CI, 15-63).",
"     </li>",
"     <li>",
"      Condom use increased and the number of episodes of rectal intercourse decreased.",
"     </li>",
"     <li>",
"      There were no differences between the arms in the number of STDs or high-risk sexual practices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prespecified subgroup analysis was performed to investigate whether drug levels correlated with a protective effect. Among the participants in the placebo group who became infected with HIV, no drug was detected in any serum specimen, as expected. This confirmed that no patient in the placebo arm used antiretroviral medications. In the intervention arm assigned to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    daily, drug was detected in 3 of 34 randomly selected subjects with newly acquired HIV infection (9 percent) compared with 22 of 43 participants who did not acquire HIV (51 percent) suggestive of a protective effect of the study drugs. A follow-up study confirmed that those who acquired HIV infection were less likely to have detectable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    levels in the serum or peripheral blood mononuclear cells&nbsp;within a month of infection&nbsp;compared with matched controls who did not become infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/5\">",
"     5",
"    </a>",
"    ]. These results suggest that the modest efficacy of the intervention may have been due to lack of adherence. Of note, patient self-report of drug adherence was much higher than suggested by objective drug monitoring, despite the fact that the assay would have detected drug taken up to 14 days earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1251769\">",
"    <span class=\"h2\">",
"     Clinical data in heterosexual individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large trials in heterosexual individuals at high risk for sexual acquisition of HIV have demonstrated efficacy with pre-exposure prophylaxis with antiretroviral agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A controlled trial (Partners-PrEP) in Kenya and Uganda demonstrated that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      , was efficacious, compared with a placebo, for the prevention of HIV acquisition among 4758 discordant couples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14\">",
"       14",
"      </a>",
"      ]. Tenofovir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      use decreased the risk of HIV infection by 67 and 75 percent, respectively (17 and 13 infections compared with 52 infections in the placebo arm).",
"     </li>",
"     <li>",
"      In a separate trial of 1200 sexually active heterosexual women and men in Botswana (TDF2), the rate of HIV infection was similarly decreased by 62 percent among patients randomly assigned to daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (1.2 events per 100 person years) compared with placebo (3.1 events per 100 person years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/15\">",
"       15",
"      </a>",
"      ]. A major limitation of this study, however, was the high study noncompletion rate, approximately 33 percent in both arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from both these trials highlighted the importance of adherence to study medications in maintaining the efficacy of pre-exposure prophylaxis. Patients in the intervention arms of both the Partners-PrEP and TDF2 trials who became infected were less likely to have detectable plasma",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    levels than those who remained uninfected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Significant discrepancies were observed between patient reports of adherence or pill counts and measured drug levels.",
"   </p>",
"   <p>",
"    With regards to serodiscordant couples, antiretroviral therapy (ART) for the HIV-infected partner alone is also highly effective at reducing HIV transmission. While these two strategies have not been compared directly, ART for the HIV-infected partner has the additional benefit of possibly reducing the AIDS and non-AIDS morbidity and mortality for that individual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9400768\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among heterosexual women, trials of pre-exposure prophylaxis against HIV, with both oral and topical formulations of antiretrovirals, have yielded more variable results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844453\">",
"    <span class=\"h4\">",
"     Oral chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data have raised questions about the efficacy of oral chemoprophylaxis for high-risk HIV-seronegative women who are sexually active. The conflicting trial results are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the female HIV-negative partners in the Partners-PrEP trial of serodiscordant couples, the risk of HIV infection was decreased by 71 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (8 of 595 women infected) and 66 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (9 of 566 infected) compared with placebo (28 of 619 infected) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14\">",
"       14",
"      </a>",
"      ]. The number of serious adverse events and pregnancies were similar among the three arms. Women who became pregnant had study medications discontinued; no pregnancy complications were observed.",
"     </li>",
"     <li>",
"      There was also a trend towards 50 percent fewer infections with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      prophylaxis than placebo among the 557 women in the TDF2 trial of at-risk heterosexual individuals in Botswana, although the difference was not statistically significant in this subpopulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, another placebo-controlled clinical trial (FEM-PrEP), which was conducted among approximately 2000 sexually active African women, was halted when an interim assessment showed no evidence of protective efficacy among those assigned to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      arm (4.7 compared with 5 infections per 100 person years with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. In addition, women in the intervention arm had higher rates of pregnancy compared with those in the placebo arm, suggesting that they were having more unprotected intercourse. However, less than one quarter of the subset of FEM-PrEP participants who were assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      and underwent therapeutic drug monitoring had detectable plasma drug levels, suggesting a role of substantial non-adherence in the failure to demonstrate a protective effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These results were followed by the premature termination of the oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      arm in another clinical trial (Vaginal and Oral Interventions to Control the Epidemic; VOICE trial), which was conducted among 5000 African women who were randomly assigned to oral tenofovir alone, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      , placebo pill, or tenofovir gel or placebo gel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/19\">",
"       19",
"      </a>",
"      ]. The oral tenofovir arm was discontinued because the Data Safety Monitoring Board determined that the trial would not be able to demonstrate that this intervention was efficacious. The TDF-FTC arm of the trial is still in progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible explanations for these disparate findings include low rates of adherence, unanticipated drug-drug interactions, or other possible factors; in-depth analyses are in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/20\">",
"     20",
"    </a>",
"    ]. As above, non-adherence was a substantial issue in the FEM-PreP trial. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844460\">",
"    <span class=\"h4\">",
"     Vaginal chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable results have also been reported with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in a vaginal gel formulation.",
"   </p>",
"   <p>",
"    In a double-blind, randomized controlled trial (CAPRISA 004), 444 sexually active HIV-seronegative women from South Africa were instructed to insert one dose of a 1% vaginal gel formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    or placebo within 12 hours before and after sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/21\">",
"     21",
"    </a>",
"    ]. Over a 30-month period, study participants were assessed at monthly follow-up visits with HIV and pregnancy testing, while hematologic, hepatic and renal function was assessed at 3, 12, and 24 months. The trial results demonstrated the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      gel had a 39 percent reduction in the risk of HIV acquisition (5.6 versus 9.1 infections per 1000 persons). The protective effect of tenofovir gel was evident irrespective of other risks of HIV acquisition (eg, sexual behavior, condom use, or presence of HSV-2 infection).",
"     </li>",
"     <li>",
"      Furthermore, a higher level of adherence corresponded to a lower incidence of HIV infection (risk reduction 54, 38, and 28 percent, respectively, among those with high, intermediate, and low rates of adherence).",
"     </li>",
"     <li>",
"      No difference was observed in adverse events between the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and placebo gel arms.",
"     </li>",
"     <li>",
"      There was also no evidence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      resistance among those who did acquire HIV infection during the study.",
"     </li>",
"     <li>",
"      Despite an intensive adherence program, about 40 percent of the women in this study had adherence rates below 50 percent. This finding highlights the need for new methods of enhancing adherence in future trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study terminated its daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    gel arm because an independent Data Safety and Monitoring Board determined that daily tenofovir gel use was not clearly more protective than the placebo gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons for the contrasting results from these two studies are unclear. A dedicated analysis of the lack of efficacy in the VOICE study has not yet been completed, since the oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    arm of the trial is still underway as of the end of 2012. The successful CAPRISA 004 study evaluated pericoital dosing, raising the possibility that less frequent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    gel dosing (ie, only pericoital) could be preferable to daily dosing. Additionally, there may have been different patterns of adherence that contributed to the difference in efficacy.",
"   </p>",
"   <p>",
"    Additional studies are ongoing to further evaluate the efficacy of vaginal chemoprophylaxis against HIV infection. Topical administration remains an attractive intervention because of its safety and the high drug concentrations in the genital mucosa that are achieved with gel applications compared with oral formulations. As an example, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    produces cervicovaginal tissue concentrations 1 percent of those obtained after topical tenofovir gel administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, rectal concentrations of tenofovir after oral administration are much higher, possibly explaining the increased efficacy of oral tenofovir among MSM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3027239\">",
"    <span class=\"h3\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Partners-PrEP trial of serodiscordant couples and the TDF2 trial of heterosexual individuals in Botswana described above, over half of the individuals in whom pre-exposure prophylaxis was tested were men. (See",
"    <a class=\"local\" href=\"#H5844453\">",
"     'Oral chemoprophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These trials suggested that pre-exposure prophylaxis is effective in reducing HIV infection among uninfected men. Among the male HIV-negative partners in the Partners-PrEP trial, the risk of infection was reduced 63 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (9 of 984 men infected) and 84 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (4 of 1010 infected) compared with placebo (24 of 959 infected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14\">",
"     14",
"    </a>",
"    ]. The TDF2 trial similarly demonstrated a risk reduction in HIV infection of 80 percent with tenofovir-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (2 of 331 men infected) compared with placebo (10 of 331 infected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740736\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    have been generally well tolerated in studies to date.",
"   </p>",
"   <p>",
"    In a study designed to evaluate the safety of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    verus placebo among 400 men who have sex with men (MSM) in the United States, preliminary data suggest that there were no significant safety differences between the two arms; specifically, there were no clinically significant changes in renal function or bone demineralization related to tenofovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/24\">",
"     24",
"    </a>",
"    ]. Although patients assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    had greater declines in z-scores at the hip, lumbar spine, and forearm compared with those taking placebo in the TDF2 trial, there were no differences in the rate of fractures, which were all traumatic, between the two groups during the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the iPrEX trial, nausea was more common in the intervention group (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    ) during the first four weeks of the trial, along with unintentional weight loss of 5 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. Trials of prophylaxis in heterosexual men and women have also noted a higher rate of nausea and vomiting but no excess of serious adverse effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatinine elevations occurred in similar proportions of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or placebo in most pre-exposure prophylaxis trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ]. In the iPrEX trial, a total of 10 creatinine elevations led to discontinuation of a study drug (seven in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    group and three in the placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. Study drugs were restarted in nine subjects. Serum creatinine became elevated again in five patients on tenofovir-emtricitabine; all but one elevation resolved with treatment discontinuation. &nbsp;",
"   </p>",
"   <p>",
"    These numbers may be somewhat conservative however, since many of the patients were not taking study drug as prescribed, and participants were being monitored monthly.",
"   </p>",
"   <p>",
"    Another potential adverse event associated with long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    use includes flares of hepatitis B infection among those with chronic infection, though none have been seen in the pre-exposure prophylaxis trials to date. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740852\">",
"    <span class=\"h1\">",
"     BEHAVIORAL CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although concerns have been raised that offering pre-exposure prophylaxis (PrEP) for HIV may encourage increased levels of sexual risk activity, this has not been borne out by the iPrEX trial, a Centers for Disease Control and Prevention-sponsored study of 400 American men who have sex with men, or another pre-exposure prophylaxis trial of a topical gel that enrolled at-risk women in South Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13,21,24\">",
"     13,21,24",
"    </a>",
"    ]. However, patients in these trials were aware of the possibility of being randomly assigned to the placebo arm.",
"   </p>",
"   <p>",
"    The possibility of disinhibition will need to be addressed in future trials that have two intervention arms, particularly since study participants will be counseled regarding the partial efficacy seen thus far in PrEP studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740786\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE IN CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major concern regarding the use of pre-exposure prophylaxis (PrEP) is the possibility of acquired drug resistance if HIV infection is transmitted. This is a particular concern regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , since these drugs are the mainstay of treatment in the treatment-naive patient.",
"   </p>",
"   <p>",
"    Although the genetic barrier to resistance is low with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , the genetic barrier to resistance for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is high. The development of M184V mutation abrogates the antiviral activity of emtricitabine, but makes HIV less replication competent, while three mutations are required for any significant impact on tenofovir activity. Of note, although there is a single mutation (ie, K65R), which can severely affect tenofovir activity in vitro, it is uncommonly seen in clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=see_link\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The iPrEX trial did not demonstrate any incident",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    drug resistance, although the low level of adherence of many of the patients in the intervention arm does not eliminate the possibility of this scenario [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. Among the 36 patients in the intervention group and the 64 patients in the placebo group who became infected with HIV during the trial, no emergent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or tenofovir resistance was detected. In contrast, of the 33 women in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    arm of the Fem-Prep trial who became infected with HIV, four were infected with viruses that contained a mutation at the M184 position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/17\">",
"     17",
"    </a>",
"    ]. No tenofovir resistance mutations were detected.",
"   </p>",
"   <p>",
"    In these clinical trials, the emergence of resistance mutations was more prevalent among patients who were retrospectively found to be HIV-infected at enrollment. In the iPrEX trial, HIV RNA was retrospectively detected among ten subjects at study enrollment who had two negative HIV antibody tests prior to randomization, but became HIV-infected by week four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. One patient, who was infected with wild-type HIV at baseline, subsequently developed an M184V mutation after four weeks of prophylaxis, implying the development of drug resistance after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    exposure. In two other cases, the participants were probably infected with HIV that already was resistant to emtricitabine.",
"   </p>",
"   <p>",
"    Similarly, the Partners PrEP study did not find M184V or K65R mutations in any subject who acquired HIV infection following randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/25\">",
"     25",
"    </a>",
"    ]. However, among the eight subjects who were retrospectively found to be HIV-infected at randomization, one developed the M184V mutation and another, K65R. &nbsp;",
"   </p>",
"   <p>",
"    These findings highlight the importance of diagnosing underlying HIV infection prior to initiating pre-exposure prophylaxis to avoid selection of mutations that confer drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94403822\">",
"    <span class=\"h1\">",
"     APPROACH TO PRE-EXPOSURE PROPHYLAXIS AGAINST HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In July 2012, the United States Food and Drug administration approved the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    as pre-exposure prophylaxis for confirmed HIV-negative individuals at high risk for sexually-acquired HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/26\">",
"     26",
"    </a>",
"    ]. However, there are still many limitations to the available data and further studies are needed to determine the optimal strategies for this approach.",
"   </p>",
"   <p>",
"    Nevertheless, in light of emerging efficacy data as well as concerns regarding the use of pre-exposure prophylaxis in clinical practice without proper guidance on patient monitoring, we agree with the United States Centers for Disease Control (CDC) interim guidelines for the use of antiretroviral medications among patients considered at high risk for HIV acquisition (",
"    <a class=\"graphic graphic_table graphicRef52982 \" href=\"mobipreview.htm?12/55/13181\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94403842\">",
"    <span class=\"h2\">",
"     Candidates for pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal candidates for pre-exposure prophylaxis have yet to be fully defined and clinicians must evaluate the pros and cons of pre-exposure prophylaxis on an individual patient basis.",
"   </p>",
"   <p>",
"    Clinical studies to date have suggested efficacy among men who have sex with men, serodiscordant couples, and heterosexual individuals in areas of high HIV prevalence. (See",
"    <a class=\"local\" href=\"#H7740706\">",
"     'Clinical data in men who have sex with men'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1251769\">",
"     'Clinical data in heterosexual individuals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, a recurring theme in all these studies is the importance of adherence to maintain efficacy; thus, any patient for whom pre-exposure prophylaxis is considered should be highly motivated to take the regimen consistently and attend regular follow-up for clinical monitoring and behavioral counseling. Furthermore, pre-exposure prophylaxis is not an appropriate option for patients who demonstrate erratic behavior with regard to medication and appointment adherence not only because of decreased efficacy but also because of an increased risk of selection for a resistant strain of HIV.",
"   </p>",
"   <p>",
"    For HIV-uninfected patients who are at high risk for sexually-acquired HIV and are committed to medication adherence and close follow-up, we suggest pre-exposure prophylaxis in addition to counseling on other risk reduction methods, such as behavioral modification and consistent condom use, in order to reduce the risk of HIV infection. Specifically, these high-risk populations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who have sex with men (MSM) who engage in high-risk sexual behavior (eg, unprotected anal sex with partners known to be HIV-infected, sex with multiple or anonymous partners). &nbsp;",
"     </li>",
"     <li>",
"      Heterosexual men and women who have multiple sex partners in areas of high HIV prevalence (eg, sub-Saharan Africa, and possibly some high-prevalence urban areas in the United States) and are unlikely or unable to use condoms consistently.",
"     </li>",
"     <li>",
"      HIV-uninfected partners of a serodiscordant couple, when consistent antiretroviral therapy (ART) for the HIV-infected partner is not feasible, either because of resource constraints or suboptimal medication adherence. Because adequate suppression of HIV plasma viremia may take 6 to 12 weeks, pre-exposure prophylaxis may also be indicated for the uninfected partner when the infected partner has only recently initiated a treatment regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As examples, pre-exposure prophylaxis, if taken consistently, may be particularly useful for commercial sex workers (if condom use is not acceptable to their clients) or women attempting to conceive with an HIV-infected man.",
"   </p>",
"   <p>",
"    Apart from confirming that candidates are HIV-uninfected, it is also important to ensure that they do not have underlying medical problems that would preclude safe use of the pre-exposure prophylaxis regimen (eg, creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    Additionally, patients with chronic hepatitis B are at risk for hepatitis flares if medication is discontinued, so the risks of using pre-exposure prophylaxis for these patients may outweigh the benefits unless treatment of hepatitis B infection is warranted, in which case",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    could be used for both purposes.",
"   </p>",
"   <p>",
"    Pre-exposure prophylaxis has not been specifically studied in pregnant women, so it is unclear if consistent prophylaxis use would be as protective as for non-pregnant women.",
"   </p>",
"   <p>",
"    Of note, pre-exposure prophylaxis has only been studied in individuals at risk for sexually acquired HIV. Studies of pre-exposure prophylaxis in injection drug users are ongoing but there are no data yet to support its use in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740745\">",
"    <span class=\"h2\">",
"     Evaluation for pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have HIV antibody testing prior to prophylaxis to be certain that they do not have unsuspected chronic HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC recommends testing for acute HIV infection if a patient has symptoms consistent with this syndrome. Patients with acute HIV infection often have viral syndrome symptoms (eg, lymphadenopathy, fever, malaise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a maculopapular eruption) and viremia (ie, detectable plasma HIV RNA) in the absence of HIV antibody. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the iPrEX trial, HIV testing at enrollment demonstrated that 10 patients with a variety of symptoms had unsuspected HIV infection, two of whom were initially assigned to the intervention arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"     13",
"    </a>",
"    ]. In clinical trials of heterosexual individuals, several participants were retroactively diagnosed with HIV at enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ]. Most cases of drug resistance were documented in such patients. This illustrates that all patients with any relevant infectious symptoms who are being evaluated for initiation of pre-exposure prophylaxis should have HIV RNA testing to eliminate the possibility of acute HIV infection before exposing the patient to antiretroviral therapy that would be insufficient to treat established HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some clinicians think that all high-risk HIV-uninfected patients should have HIV RNA testing within one week of starting prophylaxis, regardless of whether or not they have symptoms of primary HIV infection. This recommendation is based on: a) the high risk of HIV acquisition among such patients who are candidates for pre-exposure prophylaxis, and b) concerns regarding the development of drug resistance if the patient has exposure to suboptimal ART during the throes of primary HIV infection (which is associated with high levels of viremia). Other clinicians may base their decision to test for HIV RNA on whether a recent high-risk exposure occurred during the past few days or weeks.",
"   </p>",
"   <p>",
"    In addition to HIV testing, patients should have the following laboratories performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum creatinine and urinalysis to determine if proteinuria or glycosuria are present, which are signs of tubular dysfunction",
"     </li>",
"     <li>",
"      Hepatitis B surface antigen and antibody to surface and core antigens (ie, anti-HBs and anti-HBc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are nonimmune to hepatitis B virus should be immunized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women should undergo initial pregnancy testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94404048\">",
"    <span class=\"h2\">",
"     Regimen for pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    in patients who opt for pre-exposure prophylaxis as it is the most widely studied regimen among various populations, and studies show only mild adverse effects compared with placebo. The regimen should be given once daily, as intermittent administration has not been clinically evaluated. It should be continued for as long as the risk of infection persists.",
"   </p>",
"   <p>",
"    The data on topical vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    have been conflicting, and further data are needed before its use for pre-exposure prophylaxis can be supported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184287\">",
"    <span class=\"h2\">",
"     Dispensing medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a decision is made to prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    , it should be dispensed as a 90-day supply, renewable only after HIV testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184312\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinical trials, patients were intensively monitored monthly for pill counts, adherence counseling, rapid testing for HIV antibodies, laboratory testing of creatinine, aminotransferases, and anemia. Patients were interviewed regularly regarding risk factors for sexually transmitted infection and examined for any possible signs of disease. Drug resistance testing was dictated based on the presence of viremia.",
"   </p>",
"   <p>",
"    Such intensive monitoring would use a significant amount of resources within outpatient clinics. Future studies will need to evaluate alternative strategies, which may be more cost effective while still providing adequate patient safety. In the interim, we agree with the CDC recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV antibody testing every two to three months and HIV testing when prophylaxis is discontinued",
"     </li>",
"     <li>",
"      Screening for symptoms of any new sexually transmitted disease (STD) every two to three months; testing and treatment as needed",
"     </li>",
"     <li>",
"      STD screening at six months, regardless of symptoms, and more often if risk behavior is suggestive",
"     </li>",
"     <li>",
"      Monitoring of serum creatinine every three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , we suggest more frequent monitoring of creatinine among patients with diabetes or hypertension, and for those with a prior history of renal insufficiency. Tenofovir-containing pre-exposure prophylaxis should be discontinued if significant declines (eg, greater than 20 percent decrease or to a creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in renal function are detected.",
"   </p>",
"   <p>",
"    Of note, some experts believe that it is important to schedule the first follow-up visit at one month following initial drug dispensation in order to assess adherence and to screen for early nephrotoxicity.",
"   </p>",
"   <p>",
"    Women who opt to take pre-exposure prophylaxis should undergo regular pregnancy testing. Pre-exposure prophylaxis has not been specifically studied in pregnant women. The potential risks and benefits of continuing pre-exposure prophylaxis should be discussed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740778\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to understand pre-exposure prophylaxis against HIV is only partially effective and that the trials that have evaluated the efficacy of antiretroviral medications included a comprehensive approach, with the use of condoms and counseling regarding high-risk behaviors. Also, patients should understand that condoms are also effective in preventing HIV transmission without the risk of systemic side effects. Patients with social or mental health issues, such as untreated depression or active drug use, will need additional referrals and interventions to address their underlying comorbidities.",
"   </p>",
"   <p>",
"    Patients should also be counseled regarding the increased risk of HIV acquisition in the setting of other genital lesions (eg, Herpes simplex virus). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1252555\">",
"    <span class=\"h1\">",
"     COST CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost considerations have been an additional concern regarding the widespread implementation of pre-exposure prophylaxis. Several studies have addressed the estimated cost-benefit ratio of dispensing pre-exposure prophylaxis on a population basis. Analyses of the cost-effectiveness of pre-exposure prophylaxis in men who have sex with men (MSM) in the United States have arrived at various results but are difficult to compare because of differences in assumptions, models, time frame, and scope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. One study based its analysis on efficacy data from the iPrEX study and costs of treatment and monitoring according to the interim Centers for Disease Control (CDC) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/32\">",
"     32",
"    </a>",
"    ]. It estimated that pre-exposure prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    in high-risk MSM in the US (those with more than five different sex partners annually) for 20 years would prevent 167,143 HIV infections over that time and cost about $50,000 USD per quality-adjusted life-year (QALY) gained. If pre-exposure prophylaxis were used in a more general population of MSM of all risk levels, the cost per QALY gained would be over three times as much and would no longer be considered in the US to be cost-effective.",
"   </p>",
"   <p>",
"    Pre-exposure prophylaxis may also be cost-effective in other populations with a high incidence of HIV. An analysis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    gel use in South African women projected a mean lifetime HIV risk reduction from 40 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34041/abstract/33\">",
"     33",
"    </a>",
"    ]. Although pre-exposure prophylaxis was not cost saving despite the marginal cost of the tenofovir gel, it was estimated to have a cost-effectiveness ratio of only $2700 USD per year of life saved.",
"   </p>",
"   <p>",
"    As in all cost-effectiveness studies, interpretation of these findings is limited by uncertainty and multiple assumptions. However, they suggest that implementing pre-exposure prophylaxis for high-risk populations can be a cost-effective measure in preventing HIV infection. Moreover, since some of these medications may be available as generic agents in the next few years, costs may decrease considerably. Nevertheless, the cost of pre-exposure prophylaxis and monitoring may be prohibitive for certain patients, and at present it is unknown what the extent of insurance or government funding coverage for this preventative strategy will be.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10888678\">",
"    <span class=\"h1\">",
"     AREAS FOR FUTURE RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other trials are underway globally in men who have sex with men (MSM), injection drug users, at-risk women, and HIV-discordant couples to examine the impact of oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal drug delivery on HIV acquisition. Future studies will need to evaluate the minimum drug exposure that is needed for protection against HIV infection, intermittent pre-exposure prophylaxis, topical versus oral preparations, and drug resistance. Protective levels may also differ by exposure route (eg, vaginal versus rectal exposure). The relative importance of the various compartments (eg, genital secretions versus serum concentrations) for drug delivery is also currently unknown. Also, it is unclear if integrated intracellular virus or free virions may be a preferential drug target in genital secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297048\">",
"    <span class=\"h1\">",
"     FURTHER INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional trials are planned to further examine the efficacy and safety of pre-exposure prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A community-based organization, the AIDS Vaccine Advocacy Coalition, continuously updates the status of clinical trials that are currently underway at",
"    <a class=\"external\" href=\"file://www.avac.org/\">",
"     www.avac.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7740894\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to two million new HIV infections still occur yearly worldwide. Pre-exposure prophylaxis with antiretroviral medications is a concept that has been widely recognized as a potential way to prevent new infections among those at risk. (See",
"      <a class=\"local\" href=\"#H7740404\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7740428\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous animal model studies have demonstrated that antiretroviral agents administered parenterally, orally, or topically before or just after retrovirus challenge is protective against HIV acquisition. (See",
"      <a class=\"local\" href=\"#H7740412\">",
"       'Animal data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several trials in various populations, including men who have sex with men, heterosexual individuals with an HIV-infected partner, and heterosexual individuals in areas of high HIV prevalence, have demonstrated a reduction in the risk of HIV infection by 44 to 75 percent with daily use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      compared with placebo. All patients also received risk reduction counseling with encouragement of condom use as well as screening and treatment for sexually transmitted diseases (STDs). The level of protection was greater among participants who were highly adherent to medication use. Studies that failed to demonstrate a protective effect may have been limited by a substantial rate of non-adherence to study medications. (See",
"      <a class=\"local\" href=\"#H49825196\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      is generally well tolerated. Patients should be informed that although some will experience mild to moderate nausea upon initiation of this agent, these symptoms tend to abate after a few days and are not a reason to discontinue medication.",
"     </li>",
"     <li>",
"      In trials of pre-exposure prophylaxis, there were no excess serious adverse effects with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      compared with placebo. Nevertheless, concerns about renal and bone toxicity with longer exposures persist and warrant routine monitoring. (See",
"      <a class=\"local\" href=\"#H7740736\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of drug resistance in the setting of pre-exposure prophylaxis trials occurred among patients who were retrospectively found to be HIV-infected at enrollment. This finding highlights the importance of diagnosing underlying HIV infection prior to initiating pre-exposure prophylaxis to avoid selection of mutations that confer drug resistance. (See",
"      <a class=\"local\" href=\"#H7740786\">",
"       'Drug resistance in clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to counseling on other risk reduction methods, including consistent condom use, for HIV-uninfected adults who are at high risk for sexually-acquired HIV and are committed to medication adherence and close follow-up, we suggest pre-exposure prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Specific high-risk populations include the following: (See",
"      <a class=\"local\" href=\"#H94403842\">",
"       'Candidates for pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Men who have unprotected anal sex with men and have multiple or anonymous sex partners",
"     </li>",
"     <li>",
"      Heterosexual individuals who have multiple sex partners in areas of high HIV prevalence",
"     </li>",
"     <li>",
"      Partners of HIV-infected individuals who have not achieved viral suppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient for whom pre-exposure prophylaxis is considered should be highly motivated to take the regimen consistently and attend regular follow-up for clinical monitoring and behavioral counseling. (See",
"      <a class=\"local\" href=\"#H94403842\">",
"       'Candidates for pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      for pre-exposure prophylaxis should be administered once daily for as long as the risk of infection persists. (See",
"      <a class=\"local\" href=\"#H94404048\">",
"       'Regimen for pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiation of pre-exposure prophylaxis, all patients should have HIV antibody testing to be certain that they do not have unsuspected chronic HIV infection. Screening for acute HIV infection in patients with recent high-risk behaviors who are initiating pre-exposure prophylaxis, regardless of the presence or absence of symptoms, should also be considered. Other routine baseline laboratories include serum creatinine and urinalysis, hepatitis B serologies, and pregnancy testing. (See",
"      <a class=\"local\" href=\"#H7740745\">",
"       'Evaluation for pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring for adherence and safety is important for patients who use pre-exposure prophylaxis. This includes regular HIV antibody testing and STD screening, as well as monitoring serum creatinine. (See",
"      <a class=\"local\" href=\"#H6184312\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should understand that condoms are highly effective in preventing HIV transmission without the risk of systemic side effects and are an important aspect of any HIV prevention strategy. (See",
"      <a class=\"local\" href=\"#H7740778\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.retroconference.org/2010/Abstracts/38023.htm (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/2\">",
"      Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50 Suppl 3:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/3\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/4\">",
"      Wang LH, Begley J, St Claire RL 3rd, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/5\">",
"      Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/6\">",
"      Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007; 21:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/7\">",
"      Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/8\">",
"      Mayer KH, Venkatesh KK. Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 2010; 55 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/9\">",
"      Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/10\">",
"      Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/11\">",
"      Garc&iacute;a-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/12\">",
"      Garc&iacute;a-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/13\">",
"      Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/14\">",
"      Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/15\">",
"      Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/16\">",
"      Stephenson J. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women. JAMA 2011; 305:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/17\">",
"      Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411.",
"     </a>",
"    </li>",
"    <li>",
"     Van Damme L, Corneli A, Ahmed K, et a and the FEM-PrEP Study Groupl. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012. Abstract #32LB",
"    </li>",
"    <li>",
"     file://www.mtnstopshiv.org/node/3619 (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/20\">",
"      Mayer KH, Krakower D. Antiretroviral medication and HIV prevention: new steps forward and new questions. Ann Intern Med 2012; 156:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/21\">",
"      Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168.",
"     </a>",
"    </li>",
"    <li>",
"     MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, November 2011. file://www.mtnstopshiv.org/node/3909 (Accessed on June 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/23\">",
"      Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.",
"     </a>",
"    </li>",
"    <li>",
"     Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir for HIV pre-exposure prophylaxis. Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     Baeten J, Donnell D, Ndase P, et al. ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012. Abstract #29.",
"    </li>",
"    <li>",
"     FDA approves first drug for reducing the risk of sexually acquired HIV infection, July 16, 2012. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm?s_cid=mm6003a1_w (Accessed on January 28, 2011).",
"    </li>",
"    <li>",
"     Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults, Morbidity and Mortality Weekly Report (MMWR), August 10, 2012 / 61(31);586-589. file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm?s_cid=mm6131a2_e (Accessed on August 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/29\">",
"      Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/30\">",
"      Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/31\">",
"      Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/32\">",
"      Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012; 156:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34041/abstract/33\">",
"      Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15810 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34041=[""].join("\n");
var outline_f33_15_34041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7740894\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740404\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740428\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740420\">",
"      PROPOSED CANDIDATE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2296983\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2296990\">",
"      Genital tract penetration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2296997\">",
"      HIV drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2296943\">",
"      HOW MANY DRUGS ARE NEEDED FOR PRE-EXPOSURE PROPHYLAXIS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2297123\">",
"      ROUTE OF DRUG EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2297164\">",
"      WHEN SHOULD PRE-EXPOSURE PROPHYLAXIS BE OFFERED?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740412\">",
"      ANIMAL DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49825196\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7740706\">",
"      Clinical data in men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6184114\">",
"      - Pre-exposure Prophylaxis Initiative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1251769\">",
"      Clinical data in heterosexual individuals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9400768\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5844453\">",
"      Oral chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5844460\">",
"      Vaginal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3027239\">",
"      - Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740736\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740852\">",
"      BEHAVIORAL CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740786\">",
"      DRUG RESISTANCE IN CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94403822\">",
"      APPROACH TO PRE-EXPOSURE PROPHYLAXIS AGAINST HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94403842\">",
"      Candidates for pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7740745\">",
"      Evaluation for pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94404048\">",
"      Regimen for pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6184287\">",
"      Dispensing medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6184312\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7740778\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1252555\">",
"      COST CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10888678\">",
"      AREAS FOR FUTURE RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2297048\">",
"      FURTHER INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7740894\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/55/13181\" title=\"table 1\">",
"      Guidance for PrEP against HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34042="Diagnostic approach to chest pain in adults";
var content_f33_15_34042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to chest pain in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     James L Meisel, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/15/34042/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/15/34042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who describes chest pain to the primary care physician represents an immediate challenge. The symptom is usually of benign etiology, but rarely it may portend imminent catastrophe. Although standard textbooks of medicine often emphasize the high-risk nature of chest pain, non-life-threatening etiologies, which may be functionally disabling, are much more common in the primary care setting and require a cost-effective approach to diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The correct diagnosis is most often derived from a vigilantly obtained, detailed history (pain description; associated symptoms; and in some cases disease risk factors) that is supported by specific physical findings, an electrocardiogram,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest x-ray.",
"   </p>",
"   <p>",
"    Importantly, the prevalence of chest pain etiologies varies according to the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/4\">",
"     4",
"    </a>",
"    ]. The causes of chest pain that are most common in primary care practice and the diagnostic approach in the office for chest pain of uncertain etiology are reviewed here. A more complete discussion of the differential diagnosis of chest pain is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY IN PRIMARY CARE POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study of 399 episodes of chest pain in patients seen in multiple outpatient centers over a one-year period noted the following prevalences of various causes of chest pain (",
"    <a class=\"graphic graphic_table graphicRef76422 \" href=\"mobipreview.htm?27/58/28587\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 60 percent of chest pain diagnoses were not \"organic\" in origin (ie, not due to cardiac, gastrointestinal, or pulmonary disease).",
"     </li>",
"     <li>",
"      Musculoskeletal chest pain accounted for 36 percent of all diagnoses (of which costochondritis accounted for 13 percent) followed by reflux esophagitis (13 percent).",
"     </li>",
"     <li>",
"      Stable angina pectoris was responsible for 11 percent of chest pain episodes; unstable angina or myocardial infarction occurred in only 1.5 percent. Nevertheless, most of the ancillary diagnostic testing used was directed toward finding or excluding a cause of coronary disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are consistent with other reports of the frequency of etiologies of chest pain in primary care practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/1,2,4,6,7\">",
"     1,2,4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of risk factors and the age of the patient population are important contributors to coronary artery disease (CHD) prevalence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .) In one retrospective review, as an example, only 7 percent of patients less than age 35 who had chest pain were diagnosed with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, the incidence of cardiac diagnoses may exceed 50 percent in patients with chest pain after the age of 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complete discussion of the differential diagnosis of chest pain is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMERGENCY RESPONSE TO CHEST PAIN IN THE OFFICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain due to myocardial infarction, pulmonary embolus, aortic dissection, or tension pneumothorax may result in sudden death. Any patient with a recent onset of chest pain, especially when the symptoms are ongoing, who may be potentially unstable based upon history, appearance, or vital signs, should be transported immediately to an emergency department in an ambulance equipped with a defibrillator. Stabilization of such patients should begin in the prehospital setting and includes intravenous access, placement of a cardiac monitor, and supplemental oxygen if breathlessness, hypoxemia, or signs of heart failure or shock are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/12\">",
"     12",
"    </a>",
"    ]. Noninvasive monitoring of oxygen saturation may be used to decide on the need for oxygen administration. A 12-lead electrocardiogram and a blood sample for cardiac enzyme measurement should be obtained if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are thought to be experiencing an acute coronary syndrome (ACS) should chew a 325 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    tablet. Sublingual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    should be given for chest pain unless the patient has relatively low blood pressure without intravenous access or has recently taken a phosphodiesterase inhibitor such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    (Viagra&trade;). Further assessment should be conducted in the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The office evaluation of new onset chest pain in stable individuals should begin with the consideration of imminently life-threatening causes (including acute coronary syndrome, pulmonary embolus, aortic dissection, pneumothorax, and esophageal rupture). This is usually accomplished using clinical judgement, along with ECG testing, and less frequently exercise testing, other noninvasive testing, or invasive angiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of chest pain in the emergency department\", section on 'Life-threatening conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H7#H7\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=see_link&amp;anchor=H2#H2\">",
"     \"Boerhaave's syndrome: Effort rupture of the esophagus\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Once a life-threatening etiology has been excluded, attempts should be made to identify the specific cause of symptoms and begin treatment. A diagnostic pattern will frequently emerge, based upon the patient's risk factors, description of the pain, and associated symptoms.",
"   </p>",
"   <p>",
"    In the primary care setting, the history (description of chest pain, associated symptoms and risk factors) and physical examination, complemented by selected tests such as an electrocardiogram or chest radiograph, allow the physician to accurately diagnose most causes of chest pain and to judge which patients likely have a benign etiology. As an example, one study found that physicians were able to correctly diagnose a nonorganic (ie, not due to cardiac, gastrointestinal, or pulmonary disease) versus organic cause of chest pain in 88 percent of patients using only the history and physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/1\">",
"     1",
"    </a>",
"    ]. In the remaining 12 percent who were misdiagnosed as having chest pain of organic etiology, most of the diagnoses were made with little confidence.",
"   </p>",
"   <p>",
"    Several studies suggest that a diagnosis of \"nonspecific\" chest pain carries risk of increased mortality, especially due to ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Thus, a diagnosis of nonspecific chest pain should be made cautiously and may indicate the need for vigilant follow-up. A diagnosis of \"noncardiac\" or \"atypical\" chest pain is not very useful outside of a coronary care setting.",
"   </p>",
"   <p>",
"    The clinical evaluation is also useful to estimate the pretest probability of organic causes of chest pain prior to undergoing diagnostic tests (eg, stress ECG testing to detect CHD or d-dimer, CT-angiography or lung perfusion scanning to detect pulmonary embolism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Pretest probability is an important component of the interpretation of these test results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chest pain history is less useful in patients suspected of having an acute coronary syndrome (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, one article reviewed studies in which at least one chest pain characteristic was described in patients subsequently found to have an ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/19\">",
"     19",
"    </a>",
"    ]. Although certain elements of the chest pain history were associated with increased or decreased likelihoods of ACS, none of them alone or in combination identified a group of patients in whom the diagnosis could be safely excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, in patients with stable, intermittent chest pain, a description of typical angina (ie, substernal discomfort, precipitated by exertion, improved with rest or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in less than ten minutes with many patients reporting radiation to shoulders, jaw, or inner arm) was a moderately strong predictor of obstructive epicardial CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/20\">",
"     20",
"    </a>",
"    ]. Other causes of anginal chest pain include valvular heart disease, pulmonary hypertension, and cardiac syndrome X. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=see_link\">",
"     \"Valvular heart disease in elderly adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient's style of presentation will influence the physician's subjective judgment and clinical reasoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/21\">",
"     21",
"    </a>",
"    ]. This was illustrated in a study of 44 male internists who were randomized to watch a video of an actress with classical angina symptoms interacting with a physician in a \"businesslike\" fashion, using a scripted interview, or the same actress and script presented in a \"histrionic\" fashion; a third group read a verbatim transcript of the interview [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/22\">",
"     22",
"    </a>",
"    ]. A cardiac cause for the chest pain was suspected by 50 and 13 percent of physicians viewing the businesslike and histrionic portrayals, respectively; the estimated incidence of CHD was 20 versus 10 percent. The internist's assessment of the risk of CHD was similar among the different groups after viewing some objective data. Nevertheless, the physicians viewing the histrionic portrayal were far less likely to pursue a cardiac workup (53 versus 93 percent). This study illustrates the importance of maintaining a high degree of diagnostic objectivity during the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Description of chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough description of the pain is an essential first step in the diagnosis of chest pain (",
"    <a class=\"graphic graphic_table graphicRef54553 \" href=\"mobipreview.htm?18/34/18988\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Descriptions of chest discomfort due to myocardial ischemia may differ depending on patients' culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/23\">",
"     23",
"    </a>",
"    ], gender, age and presence of comorbid conditions such as diabetes. The Women's Ischemia Syndrome Evaluation (WISE) study clearly documented gender differences in the diagnosis, prognosis and pathophysiology of ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/24\">",
"     24",
"    </a>",
"    ]. As another example, a study of patients undergoing exercise stress testing with perfusion imaging reviewed symptoms in 38 women and 94 men who had both angina and imaging evidence of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared with men, women rated their chest pain as more intense, used different terms to describe the pain (more often \"sharp\" and \"burning\"), and more frequently had pain and other sensations in the neck and throat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Quality of the pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain descriptors of chest pain (pleuritic, positional, sharp, reproducible with palpation) are weakly correlated with decreased likelihood of ACS, whereas as other characteristics (radiation to",
"    <span class=\"nowrap\">",
"     shoulders/arms",
"    </span>",
"    or precipitated by exertion) are associated with an increased likelihood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/19\">",
"     19",
"    </a>",
"    ]. However, these characteristics are only weakly-associated with ACS. Thus, no symptom alone or in combination allows safe discharge of patients without physical examination and diagnostic testing.",
"   </p>",
"   <p>",
"    The patient with myocardial ischemia often denies feeling chest \"pain.\" More typical descriptions include squeezing, tightness, pressure, constriction, strangling, burning, heart burn, fullness in the chest, a band-like sensation, knot in the center of the chest, lump in the throat, ache, heavy weight on chest (elephant sitting on chest), like a bra too tight, and toothache (when there is radiation to the lower jaw).",
"   </p>",
"   <p>",
"    In some cases, the patient cannot qualify the nature of the discomfort but places his or her fist in the center of the chest (the \"Levine sign\") or makes some other gesture indicating the location or type of pain (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Region or location of pain'",
"    </a>",
"    below). Patients with a history of coronary heart disease tend to have the same quality of chest pain with recurrent ischemic episodes.",
"   </p>",
"   <p>",
"    Acute chest pain with a classically ripping or tearing quality may be helpful in diagnosing acute aortic dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary embolism presents with pleuritic chest pain in only 40 to 48 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/27\">",
"     27",
"    </a>",
"    ]. The chest pain of myocarditis can be pleuritic, but it can also mimic that of myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Region or location of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic pain is often a diffuse discomfort that is difficult to localize. Pain that localizes to a small area on the chest is more likely of chest wall or pleural origin rather than visceral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/28\">",
"     28",
"    </a>",
"    ]. Referred pain is an exception as described in the next section.",
"   </p>",
"   <p>",
"    Patients may indicate the location",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nature of discomfort with a gesture. In an observational study in 202 patients admitted with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/28\">",
"     28",
"    </a>",
"    ], the following observations were noted about the predictive value of such findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gestures such as placing a fist in the center of the chest (the \"Levine sign\") or an open palm over the chest in response to questions about the type or location of chest pain had low predictive value for ischemic pain.",
"     </li>",
"     <li>",
"      Pointing at a single location with one finger (felt to be a sign indicating nonischemic pain) occurred in only eight patients, one of whom had an elevated troponin consistent with myocardial infarction.",
"     </li>",
"     <li>",
"      Patients who indicated larger areas of discomfort were more likely to have an ischemic etiology of pain than patients who indicated smaller areas of discomfort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study was performed in inpatients, so the prevalence of ischemic chest pain was probably much higher than would be seen in a primary care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of myocardial ischemia may radiate to the neck, throat, lower jaw, teeth, upper extremity, or shoulder. A wide extension of chest pain radiation increases the probability that it is due to myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17,29,30\">",
"     17,29,30",
"    </a>",
"    ]. Although pain radiating to the left arm is classically associated with coronary ischemia, radiation to the right arm may be a more useful finding. In one study, for example, 48 of 51 patients who presented to an emergency department with chest pain that radiated to the right arm suffered from coronary disease; 41 had a myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/30\">",
"     30",
"    </a>",
"    ]. Radiation to both arms is another predictor of acute myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef54553 \" href=\"mobipreview.htm?18/34/18988\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain radiation may provide a clue to other etiologies of chest pain. As an example, acute cholecystitis can present with right shoulder pain, although concomitant right upper quadrant or epigastric pain is more typical than chest discomfort. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .) Chest pain that radiates between the scapulae may be due to aortic dissection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .) The pain of pericarditis typically radiates to one or both trapezius ridges. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Chest pain'",
"    </a>",
"    .) Cervical radiculopathy may present with chest, upper back or upper extremity pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Temporal elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of the onset of chest pain may be a very useful distinguishing feature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain associated with a pneumothorax or a vascular event such as aortic dissection or acute pulmonary embolism classically has an abrupt onset with the greatest intensity of pain at the beginning.",
"     </li>",
"     <li>",
"      The onset of ischemic pain is more often gradual with an increasing intensity over time. A crescendo pattern of pain can also be caused by esophageal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      \"Functional\" or nontraumatic musculoskeletal chest pain might have a much more vague onset (",
"      <a class=\"graphic graphic_table graphicRef55901 \" href=\"mobipreview.htm?40/49/41755\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9335?source=see_link\">",
"       \"Clinical evaluation of musculoskeletal chest pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of pain is also helpful. Chest discomfort that lasts only for seconds or pain that is constant over weeks is not due to ischemia. A span of years without progression makes it more likely that the origin of pain is functional. The pain from myocardial ischemia generally lasts for a few minutes; it may be more prolonged in the setting of a myocardial infarction.",
"   </p>",
"   <p>",
"    Myocardial ischemia may demonstrate a circadian pattern. It is more likely to occur in the morning than in the afternoon, correlating with an increase in sympathetic tone (",
"    <a class=\"graphic graphic_figure graphicRef56626 graphicRef59140 \" href=\"mobipreview.htm?16/50/17185\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Provocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be asked about factors that provoke or worsen the pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discomfort that reliably occurs with eating is suggestive of upper gastrointestinal disease. Postprandial chest pain may be due to gastrointestinal or cardiac disease; in the latter case it can be a marker of severe myocardial ischemia (eg, left main or three-vessel CHD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest discomfort provoked by exertion is a classic symptom of angina, although esophageal pain can present similarly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other factors that may provoke ischemic pain include cold, emotional stress, meals, or sexual intercourse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=see_link\">",
"       \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain made worse by swallowing is likely of esophageal origin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Body position or movement, as well as deep breathing, may exacerbate chest pain of musculoskeletal origin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9335?source=see_link\">",
"       \"Clinical evaluation of musculoskeletal chest pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Truly pleuritic chest pain is worsened by respiration and may be exacerbated when lying down. Causes of pleuritic chest pain include pulmonary embolism, pneumothorax, viral or idiopathic pleurisy, pneumonia, and pleuropericarditis (",
"      <a class=\"graphic graphic_table graphicRef75028 \" href=\"mobipreview.htm?8/44/8907\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link\">",
"       \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Pleurodynia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that make the pain better should be established:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain that is reliably and repeatedly palliated by antacids or food is likely of gastroesophageal origin.",
"     </li>",
"     <li>",
"      Pain that responds to sublingual",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      is frequently thought to have a cardiac etiology or to be due to esophageal spasm. However, pain relief with nitroglycerin in an acute care setting is not helpful in distinguishing cardiac from noncardiac chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/33\">",
"       33",
"      </a>",
"      ]. In a study of 459 patients who presented to an emergency department with chest pain and were admitted to the hospital, the percentage of patients who had relief of chest pain with nitroglycerin was similar among the 141 patients with active CHD and the 275 patients without active CHD (35 versus 41 percent experienced relief) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, relief of pain following the administration of a \"GI cocktail\" (eg, viscous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and antacid) does",
"      <strong>",
"       not",
"      </strong>",
"      reliably distinguish gastrointestinal from ischemic chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, pain that abates with cessation of activity strongly suggests an ischemic origin.",
"     </li>",
"     <li>",
"      The pain of pericarditis typically improves with sitting up and leaning forward.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of pain is not a useful predictor of the presence of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/9\">",
"     9",
"    </a>",
"    ]. As many as one-third of myocardial infarctions may go unnoticed by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/38\">",
"     38",
"    </a>",
"    ]. The patient's level of concern about his symptom may, however, be commensurate with its severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated symptoms may not reliably distinguish between a cardiac and gastrointestinal origin of chest pain, which can coexist in up to 35 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/29,37,39\">",
"     29,37,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Belching, a bad taste in the mouth, and difficult or painful swallowing are suggestive of esophageal disease, although belching and indigestion also may be seen with myocardial ischemia.",
"     </li>",
"     <li>",
"      Vomiting may occur in the setting of myocardial ischemia (particularly transmural myocardial infarction) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/40\">",
"       40",
"      </a>",
"      ], in addition to gastrointestinal problems such as peptic ulcer disease, cholecystitis, and pancreatitis. Diabetic ketoacidosis, which can be precipitated by acute myocardial infarction, is another cause of vomiting.",
"     </li>",
"     <li>",
"      Diaphoresis has been more frequently associated with myocardial infarction than esophageal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17,20,41\">",
"       17,20,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of other associated symptoms may aid the diagnosis of chest pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea &mdash; Exertional dyspnea may occur when chest pain is due to myocardial ischemia and may predate the sensation of angina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/42\">",
"       42",
"      </a>",
"      ]. Dyspnea that occurs concurrently with chest pain may be due to myocardial ischemia or a number of pulmonary disorders including pathology of the airways, lung parenchyma, or pulmonary vasculature. In one report, patients with chest pain and dyspnea referred for exercise echocardiography had a higher incidence of exercise-induced ischemia and a poorer long-term prognosis than patients with chest pain alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/43\">",
"       43",
"      </a>",
"      ]. Dyspnea may be an important warning symptom whether or not chest pain is present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/44\">",
"       44",
"      </a>",
"      ]. However, in one review, dyspnea did not usefully discriminate the diagnosis of acute myocardial infarction (Likelihood ratio [LR] = 1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cough &mdash; The differential diagnosis of chest pain and cough includes infection, as well as congestive heart failure, pulmonary embolus, and neoplasm. Cough, hoarseness, or wheezing may also be the result of gastroesophageal reflux disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=see_link\">",
"       \"Gastroesophageal reflux and asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Syncope &mdash; The patient with myocardial ischemia may describe presyncope. However, syncope associated with chest pain should raise a concern for aortic dissection, a hemodynamically significant pulmonary embolus, a ruptured abdominal aortic aneurysm, or critical aortic stenosis (particularly if the patient has a history of exertional dyspnea).",
"     </li>",
"     <li>",
"      Palpitations &mdash; Patients with ischemia can feel palpitations resulting from ventricular ectopy or may have an abnormal awareness of their sinus rhythm. While atrial fibrillation is associated with chronic CHD, new onset, isolated atrial fibrillation is uncommon in patients with acute myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. The differential diagnosis of chest pain and palpitations due to new atrial fibrillation includes pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric symptoms &mdash; Symptoms of panic disorder, generalized anxiety, depression, or somatization may occur in patients with chest pain. A review of the literature found that panic disorder is present in 30 percent or more of patients with chest pain who have no or minimal CHD; it also may coexist with CHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a subgroup analysis of the Women's Health Initiative Observational Study, panic disorder was an independent risk factor for CHD in postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/48\">",
"       48",
"      </a>",
"      ]. Because panic disorder clearly has a negative long-term effect on the psychological and physical well-being of patients with chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/49\">",
"       49",
"      </a>",
"      ], it is among the psychosocial diagnoses (including domestic violence, discussed below) that should be actively considered rather than labeling the patient with \"noncardiac\" or \"atypical\" chest pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link&amp;anchor=H37#H37\">",
"       \"Differential diagnosis of chest pain in adults\", section on 'Psychogenic/psychosomatic causes of chest pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Constitutional symptoms &mdash; The elderly in particular may describe profound fatigue as the presenting complaint of myocardial infarction. More diffuse constitutional symptoms raise the concern for cancer, which is a rare cause of isolated chest pain in the primary care setting. Pleuritic chest pain and systemic symptoms prompt an evaluation for causes of serositis such as systemic lupus erythematosus or familial Mediterranean fever. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms associated with coronary heart disease in women &ndash; In a report of 515 women with an acute MI, only 57 percent reported acute chest pain; the other presenting symptoms were shortness of breath (58 percent), weakness (55 percent), and fatigue (43 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/50\">",
"       50",
"      </a>",
"      ]. Only 30 percent reported prodromal chest discomfort, meaning that women with underlying coronary heart disease are unlikely to report chest discomfort.",
"     </li>",
"     <li>",
"      Other specific symptoms and association with domestic violence &mdash; In a diverse, community-based population of 1900 primary care patients, chest pain was one of many specific physical symptoms associated with current domestic violence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True chest wall pain is not usually associated with systemic symptoms. Exceptions include pain due to chest wall neoplasm, associated intrathoracic trauma, and the constitutional symptoms or rash of herpes zoster.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical impression raised by the patient's description of pain must be interpreted together with other aspects of the history, including risk factors for various etiologies of chest pain (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/52\">",
"     52",
"    </a>",
"    ]. Knowledge about such risk factors provides important information regarding disease likelihood, which may ultimately guide the type and extent of evaluation performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history or lack of classical coronary risk factors does not usefully discriminate ischemic causes of chest pain in the acute setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of hyperlipidemia, left ventricular hypertrophy, or a family history of premature CHD increase the risk for myocardial ischemia (",
"      <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypertension is a risk factor for both CHD and aortic dissection (",
"      <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cigarette smoking is a nonspecific risk factor for serious pathology; it is associated with CHD, thromboembolism, aortic dissection, pneumothorax, and pneumonia (",
"      <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"       \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest pain is the symptom most commonly reported by cocaine users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/55\">",
"       55",
"      </a>",
"      ]. A history of cocaine use may increase the suspicion of myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/56\">",
"       56",
"      </a>",
"      ] and, less commonly, aortic dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/57\">",
"       57",
"      </a>",
"      ], pulmonary hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/58\">",
"       58",
"      </a>",
"      ], and acute pulmonary syndrome (&ldquo;crack lung&rdquo;) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/59\">",
"       59",
"      </a>",
"      ]. In one study of 3946 patients with an acute myocardial infarction, the risk of a myocardial infarction was increased 24 times over baseline in the 60 minutes after cocaine use (",
"      <a class=\"graphic graphic_figure graphicRef64056 \" href=\"mobipreview.htm?35/41/36509\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/60\">",
"       60",
"      </a>",
"      ]. Cocaine-associated myocardial infarction may also present without chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"       \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A recent infection, especially viral, may precede an episode of pericarditis or myocarditis. Other risk factors for pericarditis include a history of chest trauma, autoimmune disease, recent myocardial infarction or cardiac surgery, and the use of certain drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30392?source=see_link\">",
"       \"Etiology of pericardial disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Age alone is an important risk factor for CHD; among patients older than age 40, chest pain resulting from stable CHD or an acute coronary syndrome (unstable angina or myocardial infarction) becomes increasingly common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/54\">",
"       54",
"      </a>",
"      ]. On the other hand, elderly patients, especially women, are more likely to have non-classic presentations of coronary disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41113?source=see_link\">",
"       \"Clinical features and diagnosis of coronary heart disease in women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The majority of younger patients with chest pain due to CHD have traditional risk factors for atherosclerosis other than age. In a retrospective study of 209 patients under age 40 presenting with an acute myocardial infarction, 98 percent had at least one of the conventional coronary risk factors; 80 percent smoked cigarettes, 40 percent had a family history, 26 percent were hypertensive, and 20 percent had hyperlipidemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/62\">",
"       62",
"      </a>",
"      ]. Sympathomimetic drug use accounted for 7 percent of cases, and other, nontraditional risk factors were infrequently noted (",
"      <a class=\"graphic graphic_table graphicRef70639 \" href=\"mobipreview.htm?42/63/44027\">",
"       table 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Age can also help establish other diagnoses. As examples, men older than age 60 are most likely to suffer aortic dissection, while young men are at highest risk for primary spontaneous pneumothorax. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"       \"Primary spontaneous pneumothorax in adults\"",
"      </a>",
"      .) Young adults of both sexes are diagnosed with viral pleurisy more often than are their elders.",
"     </li>",
"     <li>",
"      A past history of CHD, symptomatic gastroesophageal reflux, peptic ulcer disease, gallstones, panic disorder, bronchospasm, or cancer is very helpful. It is important to establish if the present symptoms are similar to those which occurred when the diagnosis was previously established. A history of diabetes mellitus should heighten the concern for a nonclassic presentation of CHD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"       \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is important to exclude recent trauma to the chest. Blunt trauma can result in pneumothorax, disruption of the aorta, tracheobronchial tree and esophagus, myocardial or pulmonary contusion, or chest wall injury with associated musculoskeletal discomfort. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=see_link\">",
"       \"Post-cardiac injury syndromes\"",
"      </a>",
"      .) Esophageal perforation or rupture, albeit rare, may be a complication of recent upper endoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focused physical examination is used to support or disprove hypotheses generated by the history. Thus, the extent of the examination is primarily determined by the diagnoses that are being considered. A brief, \"core\" examination may suffice to diagnose life-threatening and common etiologies of chest pain.",
"   </p>",
"   <p>",
"    If acute coronary syndrome is suspected neither the physical examination nor the history is as potentially valuable as a diagnostic tool as the initial serial ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In this setting, the physical examination can be more useful for identifying patients at higher risk of adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general appearance of the patient suggests the severity and possibly the seriousness of the symptoms.",
"      <br/>",
"     </li>",
"     <li>",
"      A full set of vital signs can provide valuable clues to the clinical significance of the pain and may in some cases aid in establishing its origin. Vital signs can also help with risk stratification and patient disposition decisions in some cases (eg, acute myocardial infarction, pulmonary embolism or pneumonia).",
"      <br/>",
"      <br/>",
"      As an example, a marked difference in pulse or blood pressure between the two arms suggests the presence of aortic dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26\">",
"       26",
"      </a>",
"      ], although most patients with dissection do not have a pulse deficit. However, according to one study, the combination of findings of acute pain that is classically ripping or tearing in quality, the pulse or blood pressure differential, and mediastinal or aortic widening on chest film is virtually pathognomonic for aortic dissection (LR = 66) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpation of the chest wall may evoke pain; if so, the patient should be asked if this sensation is identical to the chief complaint. Chest wall tenderness may be present concomitantly with myocardial ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11\">",
"       11",
"      </a>",
"      ]. Hyperesthesia, particularly when associated with a rash, is often due to herpes zoster. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"       \"Postherpetic neuralgia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A complete cardiac examination including auscultation and palpation should be performed in a sitting and supine position to establish the presence of a pericardial rub or signs of acute aortic insufficiency or aortic stenosis. Ischemia may result in a mitral insufficiency murmur or an S4 or S3 gallop; there may also be abnormal precordial movement, especially at the apex. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determine if the breath sounds are symmetric and if wheezes, crackles or evidence of consolidation is present.",
"     </li>",
"     <li>",
"      A careful examination of the abdomen is important, with attention to the right upper quadrant, epigastrium, and the abdominal aorta.",
"     </li>",
"     <li>",
"      Focal neurologic signs in the setting of acute chest pain may be helpful in diagnosing acute aortic dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ancillary studies including an ECG (especially during an episode of chest pain or when there is no obvious noncardiac cause of chest pain) and chest radiography (when cardiac, pericardial, aortic, or pulmonary disease is a consideration) may support the initial diagnosis and help avoid missing serious etiologies of chest pain such as acute myocardial infarction or pneumothorax (",
"    <a class=\"graphic graphic_table graphicRef58430 \" href=\"mobipreview.htm?21/18/21803\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of any acute or diagnostic ECG changes may therapeutically allay patient anxiety and reduce short-term disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/65\">",
"     65",
"    </a>",
"    ]. Other specific clinical laboratory tests may be useful. As an example, pulmonary embolism may be unlikely if a d-dimer test is negative, while an initial positive troponin may help diagnose myocardial infarction. Further investigations, such as exercise ECG, myocardial perfusion, or echocardiographic stress testing, a diagnostic course of acid suppression, or lung perfusion, bone, or chest CT scanning may occasionally be required to establish specific etiologies for the chest pain (",
"    <a class=\"graphic graphic_table graphicRef74054 graphicRef52995 graphicRef61603 graphicRef77242 \" href=\"mobipreview.htm?5/18/5423\">",
"     table 7A-D",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Normal electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal ECG markedly reduces the probability that chest pain is due to acute myocardial infarction, but it does not exclude a serious cardiac etiology (particularly unstable angina). ECG findings must be considered in the context of the history and physical examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with unstable angina are much more likely to have a normal ECG than those with acute myocardial infarction. In a retrospective series of 250 patients who presented to a cardiology clinic for evaluation of recent onset chest pain, 20 percent of those with normal ECGs were found to have unstable angina; one-third of patients diagnosed with unstable angina had a normal ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/66\">",
"       66",
"      </a>",
"      ]. The false-negative rate was lower in a prospective series of emergency department patients presenting with chest pain; only 4 percent of those with a normal ECG were found to have unstable angina, but strict criteria were used to define the \"normal\" ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link&amp;anchor=H9#H9\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One review found that the likelihood ratio of acute myocardial infarction in a patient with a normal initial ECG was 0.1 to 0.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17\">",
"       17",
"      </a>",
"      ]. However, if the history and physical examination suggest a high pretest probability of an acute myocardial infarction, a normal ECG does not fully eliminate this diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17\">",
"       17",
"      </a>",
"      ]. Other series have found that 1 to 4 percent of patients with normal ECGs will have an acute infarction.",
"     </li>",
"     <li>",
"      Aortic dissection and pulmonary embolus are among the diagnoses that should be considered in patients with ongoing pain and a normal ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Abnormal electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is valuable both for risk stratification and diagnosis of acute myocardial infarction. An abnormal ECG that contains specific findings is the most important predictor of acute myocardial infarction (LR = 22 for ST elevation not known to be old, LR = 22 for Q waves, and LR = 4.5 for ST depression) (",
"    <a class=\"graphic graphic_table graphicRef58430 \" href=\"mobipreview.htm?21/18/21803\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11,17,20,67\">",
"     11,17,20,67",
"    </a>",
"    ]. Patients with an acute myocardial infarction who present with a positive initial ECG are more likely to require invasive therapy, have a complicated hospital course, or die [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with a non-ST elevation ACS, the ECG can identify patients in different risk categories. The major factors are the presence, extent, and location of ST segment depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=see_link&amp;anchor=H17#H17\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\", section on 'ECG for prognosis in UA and NSTEMI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ECG that is nonspecifically abnormal (eg, there are nonspecific ST and T wave abnormalities) is commonly seen and may or may not indicate heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"     \"ECG tutorial: ST and T wave changes\"",
"    </a>",
"    .) In one series of patients seen in the emergency department for chest pain, more than two-thirds with a nonspecifically \"abnormal\" ECG ultimately had a noncoronary diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph may assist in the diagnosis of chest pain if a cardiac, pulmonary, or neoplastic etiology is being considered. It is also useful in the acute setting to evaluate for a pleural effusion in patients with pleuritic pain and to help avoid missing infrequent but dangerous diagnoses such as aortic dissection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59322 \" href=\"mobipreview.htm?15/27/15806\">",
"     image 1",
"    </a>",
"    ), pneumothorax (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73277 \" href=\"mobipreview.htm?8/46/8928\">",
"     image 2",
"    </a>",
"    ), and pneumomediastinum. In the case of aortic dissection, however, other studies are typically necessary to make the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 percent of correctly interpreted chest films performed on patients with chest pain in an emergency setting yield clinically relevant information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one prospective series, 23 percent of chest x-rays had an abnormality that influenced therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical examination, and, in some individuals, an immediate ECG and chest radiograph should be sufficient to allow the clinician to form a hypothesis regarding the etiology of pain (eg, musculoskeletal, cardiac, gastrointestinal, pulmonary, psychogenic, or other etiology). For select patients with possible low-risk ACS or chronic stable CAD, an accelerated diagnostic protocol or rapid outpatient stress testing may provide important risk or diagnostic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/63\">",
"     63",
"    </a>",
"    ]. More specific studies or therapeutic trials (such as myocardial perfusion or echocardiographic stress testing, a diagnostic course of acid suppression, or lung perfusion, bone, or chest CT scanning) may be required to establish specific etiologies for chest pain. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Expanded information for algorithm'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other tools for diagnosing acute, potentially life-threatening chest pain are available, including clinical prediction rules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26,72,73\">",
"     26,72,73",
"    </a>",
"    ], coronary artery calcium score, and novel biomarkers for ACS (eg, brain natriuretic peptide) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Since none have been shown to be sensitive enough to be fully relied upon in the acute setting, clinical judgment and traditional diagnostic testing remain a central part of the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ALGORITHM FOR THE APPROACH TO THE DIAGNOSIS OF CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to the diagnosis of chest pain is outlined in the algorithm below. The approach is not regimented since the specific diagnosis of chest pain requires integration of data about the patient's risk factors, description of pain, and associated symptoms, as well as the physical examination and electrocardiogram or chest radiograph. The components of this algorithm are evidence based wherever possible, but the sum of its parts has not been validated by any clinical studies. It should not be construed as a practice guideline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnostic algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step prior to following the algorithm below is to perform a focused history and physical examination, and consider performing an ECG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest x-ray. Once a life-threatening etiology has been excluded, attempts should be made to identify the specific cause of symptoms and begin treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1 (Evaluate need for emergent care) &mdash; Consider potentially life-threatening causes of chest pain. Patients in whom an",
"      <strong>",
"       acute coronary syndrome",
"      </strong>",
"      (acute myocardial infarction or unstable angina) is suspected should receive emergent care (this generally includes chewing an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      while awaiting transport to an emergency department, ideally via an ambulance equipped with a defibrillator). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Emergency response to chest pain in the office'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Emergent care should also be provided to patients who appear to be seriously ill and to patients in whom there is a suspicion of a",
"      <strong>",
"       critical noncoronary diagnosis",
"      </strong>",
"      such as pulmonary embolus, pneumothorax, aortic dissection, esophageal rupture, or acute abdomen. For patients who do not require emergent care, proceed to Step 2.",
"     </li>",
"     <li>",
"      Step 2 (Emergent care not needed) &mdash; In patients in whom a diagnosis of stable CHD appears likely based on symptoms that are suggestive of angina",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of cardiac risk factors (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Risk factors'",
"      </a>",
"      above), proceed to Step 3; otherwise, proceed to Step 5.",
"     </li>",
"     <li>",
"      Step 3 (Symptoms consistent with stable angina) &mdash; Evaluate the patient for CHD (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"       \"Stress testing for the diagnosis of coronary heart disease\"",
"      </a>",
"      ), and consider starting outpatient management (therapy may include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , beta blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and education about the need for emergency care) or admitting the patient to the hospital, especially if symptoms are progressive. If there is a concern for angina secondary to valvular heart disease (eg, critical aortic stenosis), perform an echocardiogram prior to stress testing. Consider other causes of anginal chest pain, such as cardiac syndrome X and pulmonary hypertension. If the results of the evaluation do not demonstrate CHD, proceed to Step 4; otherwise, proceed to step 8.",
"     </li>",
"     <li>",
"      Step 4 (Evaluation for CHD was negative) &mdash; Evaluate the patient for gastrointestinal disease. This evaluation may initially involve a trial of acid suppression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=see_link\">",
"       \"Chest pain of esophageal origin\"",
"      </a>",
"      .) If there is no diagnosis and symptoms persist, proceed to step 6; otherwise, proceed to step 8.",
"     </li>",
"     <li>",
"      <strong>",
"       Step 5 (Symptoms not suggestive of angina)",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Step 5a",
"      </strong>",
"      &mdash; For patients who are felt not to have an ischemic etiology for chest pain but who have significant",
"      <strong>",
"       risk factors for CHD",
"      </strong>",
"      , consider arranging for an evaluation for CHD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    ) while proceeding to Step 5b.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Step 5b",
"      </strong>",
"      &mdash; If symptoms suggest a",
"      <strong>",
"       musculoskeletal",
"      </strong>",
"      etiology, a trial of an NSAID is appropriate; otherwise, proceed to step 5c. If pain persists, consider rib films, a bone scan, and plain or CT chest radiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9335?source=see_link\">",
"     \"Clinical evaluation of musculoskeletal chest pain\"",
"    </a>",
"    .) If there is no diagnosis and symptoms persist, proceed to step 6; otherwise, proceed to step 8.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Step 5c",
"      </strong>",
"      &mdash; If symptoms suggest a",
"      <strong>",
"       gastrointestinal",
"      </strong>",
"      etiology, evaluate the patient for gastrointestinal disease; otherwise, proceed to step 5d. This evaluation may initially involve a trial of acid suppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .) If there is no diagnosis and symptoms persist, proceed to step 6; otherwise, proceed to step 8.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Step 5d",
"      </strong>",
"      &mdash; If symptoms suggest a",
"      <strong>",
"       psychogenic",
"      </strong>",
"      etiology, evaluate the patient for a psychosocial source of chest pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    ); otherwise, proceed to step 5e. Diagnostic strategies may include a therapeutic trial of an antidepressant medication or a psychiatric referral. If there is no diagnosis and symptoms persist, proceed to step 6; otherwise, proceed to step 8.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Step 5e",
"      </strong>",
"      &mdash; Consider chest anatomy as a guide to",
"      <strong>",
"       other",
"      </strong>",
"      less common causes of non-life-threatening chest pain including: chest wall pain (eg, zoster, breast disease); other cardiac pain such as pericarditis; pathology of the lung parenchyma, vasculature, or pleura; and pain referred to the chest from the gallbladder, diaphragm, or from a disc herniation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 6 (Persistent chest pain) &mdash; If chest pain persists and evaluations for CHD (as in step 5a), musculoskeletal pain (as in step 5b), gastrointestinal pain (as in step 5c), psychogenic pain (as in step 5d), and other causes (as in step 5e) have not all been performed, those evaluations should now be undertaken.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there is no diagnosis and symptoms persist, proceed to step 7; otherwise, proceed to step 8.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 7 (Diagnostic evaluations negative) &mdash; Patient likely has chronic idiopathic chest pain. Since this is known to cause significant disability, consider referral to a pain management center or medical symptom reduction program. No further evaluation is required unless the patient has a change in symptoms or the symptoms are disabling.",
"     </li>",
"     <li>",
"      Step 8 (Cause of chest pain diagnosed) &mdash; Proceed with therapy or additional evaluation as appropriate for the diagnosed condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Expanded information for algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician's first step in the evaluation of any patient with recent chest discomfort is to exclude life-threatening illness, including ACS, pulmonary embolism, aortic dissection, pneumothorax and esophageal rupture. ACS is the most common of the etiologies requiring immediate hospitalization. One study found that patients may present to the primary care provider for evaluation in the month preceding admission for acute myocardial ischemia, suggesting the need for clinicians to be vigilant for and correctly interpret early or nonclassic symptoms of ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/77\">",
"     77",
"    </a>",
"    ]. The primary care provider may therefore play an important role in early diagnosis.",
"   </p>",
"   <p>",
"    Consideration of all information in the history, physical examination, ECG, and chest radiograph will determine whether ACS or alternative diagnoses are more or less likely. In these patients for whom the likelihood of ACS is neither high nor low, decisions will need to be made in part based upon other factors such as patient proximity to a health care facility, ability to comply with specific provider recommendations, family support system, patient and practitioner preferences, and the ability to perform an outpatient stress testing promptly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient features, any one of which should alert the clinician to a high likelihood of ACS in a patient who does not have clear ST elevations on ECG, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Worsening in the frequency, intensity, duration, and timing (eg, nocturnal pain, rest pain) of prior anginal or anginal equivalent symptoms",
"     </li>",
"     <li>",
"      New onset symptoms of shortness of breath, nausea, sweating, extreme fatigue in a patient with a known history of cardiovascular disease",
"     </li>",
"     <li>",
"      Onset of typical anginal symptoms in a patient without a history of cardiovascular disease",
"     </li>",
"     <li>",
"      New findings on physical examination of murmur (or worsening of a previously noted murmur), hypotension, diaphoresis, rales or pulmonary edema",
"     </li>",
"     <li>",
"      Transient ST deviation (&ge; 1 mm) or T wave inversion in multiple precordial leads.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features that need to be considered but are not as predictive as the high likelihood ones include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 70 years",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Extracardiac vascular disease",
"     </li>",
"     <li>",
"      Either fixed Q waves or ST depression of 0.5 to 1 mm or T-wave inversion &gt; 1mm on ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary care clinician's response to the patient with possible ischemic chest pain may include emergent hospitalization, immediate or scheduled stress testing, or cardiology consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/79\">",
"     79",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Emergency response to chest pain in the office'",
"    </a>",
"    above.). An",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    Task Force on Practice Guidelines has published recommendations for the clinical assessment of patients with possible ischemic chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/63,64,80\">",
"     63,64,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergent hospitalization is necessary for patients with suspected acute myocardial infarction or, usually, unstable angina [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/81\">",
"       81",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise stress testing is indicated for patients with a suspected ischemic heart disease who do not have an unstable coronary syndrome (eg, acute myocardial infarction or unstable angina). The indications and options for exercise testing are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"       \"Stress testing for the diagnosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although not recommended in the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/80\">",
"       80",
"      </a>",
"      ], transthoracic echocardiography (TTE) can identify regional wall motion abnormalities within seconds of acute coronary artery occlusion and thus may be a useful adjunct to the standard evaluation for cardiac ischemia. TTE is also appropriate to assist in the identification of other causes of chest pain, such as pericarditis with effusion, aortic dissection, and possibly pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24342?source=see_link\">",
"       \"Transthoracic echocardiography for the evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, acute rest radionuclide myocardial perfusion imaging (rMPI) is a sensitive test for detecting acute myocardial infarction, particularly if the chest pain is ongoing at the time of the study. It can be used to assist in emergency department triage of patients with chest pain. The specificity of acute rest rMPI is limited in patients with a previous myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3496?source=see_link\">",
"     \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiology consultation should be considered when the diagnosis of chest pain is not clear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sublingual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or long-acting nitrates is indicated in a patient who has a high likelihood of ischemic coronary disease on the basis of the clinical evaluation while awaiting an outpatient diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once ACS and other life-threatening etiologies are not felt to be reasonable diagnostic considerations, one may then skip to evaluation and management of the most likely etiology. An exception is new anginal-quality pain that is suspected to be of gastrointestinal origin in patients at risk of coronary disease; in this case, a cardiac evaluation should be considered even as other therapy is begun. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation for gastrointestinal disease follows if the cardiac work-up is negative since up to 60 percent of patients with angina-like chest pain and normal coronary angiograms will have evidence of gastrointestinal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. An adequate trial of acid suppression for gastroesophageal disease may obviate the need for further diagnostic testing and is probably cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/83\">",
"     83",
"    </a>",
"    ]; if more extensive diagnostic testing is necessary, it should be performed while the patient is still on acid suppression therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/84\">",
"     84",
"    </a>",
"    ]. Further diagnostic testing should be considered for patients with concerning symptoms or signs for cancer, such as unexplained weight loss, anemia, or gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of peptic ulcer disease\", section on 'Gastric carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of chest wall pain should not be made until other causes have been thoughtfully excluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with active myocardial ischemia can also have chest wall tenderness that may or may not be reproducible by palpation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11,85\">",
"       11,85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other causes of \"pleuritic\" chest pain, such as pulmonary embolism, must also be considered. A reduced PaO2 or increased alveolar-arterial gradient may suggest the diagnosis of pulmonary embolism; however, the PaO2 is between 85 and 105 mmHg in approximately 18 percent of patients with pulmonary embolism, and up to 6 percent may have a normal alveolar-arterial gradient for oxygen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/86\">",
"       86",
"      </a>",
"      ]. Of note, chest pain due to pulmonary embolism may be persistent rather than pleuritic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the evaluation of isolated chest wall pain reveals no evidence of rheumatic disease, infection, tumor, or other systemic illness, it is reasonable to defer ancillary studies and prescribe a therapeutic trial of antiinflammatory medication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9335?source=see_link\">",
"     \"Clinical evaluation of musculoskeletal chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic noncardiac chest pain has an excellent physical prognosis, but it is associated with significant long-term psychosocial debility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. One study found that patients with functionally disabling chest pain, both with and without heart disease, were much more likely to suffer from a host of debilitating psychiatric conditions and demand more frequent medical attention than were patients who remained active despite chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/15/34042/abstract/89\">",
"     89",
"    </a>",
"    ]. Given the disability suffered by patients with chronic chest pain, a psychiatric (eg, panic disorder) or psychosocial diagnosis should be explored if there is other supporting clinical evidence. Such patients may also feel reassured if a specific diagnosis and therapy can be offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"       \"Patient information: Chest pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"       \"Patient information: Chest pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common etiologies of chest pain in primary care practice include musculoskeletal and gastrointestinal causes, followed by cardiac, psychiatric, pulmonary, and other causes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology in primary care populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient with a recent onset of chest pain who may be potentially unstable based upon history, appearance, or vital signs, should be transported immediately to an emergency department. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Emergency response to chest pain in the office'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial goal in the office evaluation of chest pain in stable individuals is to exclude acute coronary syndrome (ACS) and other potentially life-threatening conditions. This is usually accomplished with the history, physical examination, and certain ancillary studies (eg, ECG, chest radiograph, and further testing for ACS, pulmonary embolism, or aortic dissection as indicated). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"       \"Stress testing for the diagnosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"       \"Overview of the care of patients with stable ischemic heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After life-threatening conditions have been ruled out, evaluation of other causes of chest pain is warranted. The evaluation should be guided by the results of the initial clinical assessment, including history and physical examination. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Algorithm for the approach to the diagnosis of chest pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/1\">",
"      Martina B, Bucheli B, Stotz M, et al. First clinical judgment by primary care physicians distinguishes well between nonorganic and organic causes of abdominal or chest pain. J Gen Intern Med 1997; 12:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/2\">",
"      Svavarsd&oacute;ttir AE, J&oacute;nasson MR, Gudmundsson GH, Fjeldsted K. Chest pain in family practice. Diagnosis and long-term outcome in a community setting. Can Fam Physician 1996; 42:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/3\">",
"      Agarwal M, Mehta PK, Bairey Merz CN. Nonacute coronary syndrome anginal chest pain. Med Clin North Am 2010; 94:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/4\">",
"      Buntinx F, Knockaert D, Bruyninckx R, et al. Chest pain in general practice or in the hospital emergency department: is it the same? Fam Pract 2001; 18:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/5\">",
"      Klinkman MS, Stevens D, Gorenflo DW. Episodes of care for chest pain: a preliminary report from MIRNET. Michigan Research Network. J Fam Pract 1994; 38:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/6\">",
"      An exploratory report of chest pain in primary care. A report from ASPN. J Am Board Fam Pract 1990; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/7\">",
"      B&ouml;sner S, Becker A, Haasenritter J, et al. Chest pain in primary care: epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009; 15:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/8\">",
"      Luke LC, Cusack S, Smith H, et al. Non-traumatic chest pain in young adults: a medical audit. Arch Emerg Med 1990; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/9\">",
"      Pryor DB, Harrell FE Jr, Lee KL, et al. Estimating the likelihood of significant coronary artery disease. Am J Med 1983; 75:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/10\">",
"      Goldman L, Weinberg M, Weisberg M, et al. A computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N Engl J Med 1982; 307:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/11\">",
"      Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med 1985; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/12\">",
"      O'Connor, RE, Bossaert, L, Arntz, H-R, et, al. On Behalf of the Acute Coronary Syndrome Chapter Collaborators. Part 9: acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Circulation 2010; 122:S427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/13\">",
"      Wilhelmsen L, Rosengren A, Hagman M, Lappas G. \"Nonspecific\" chest pain associated with high long-term mortality: results from the primary prevention study in G&ouml;teborg, Sweden. Clin Cardiol 1998; 21:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/14\">",
"      Ruig&oacute;mez A, Rodr&iacute;guez LA, Wallander MA, et al. Chest pain in general practice: incidence, comorbidity and mortality. Fam Pract 2006; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/15\">",
"      Robinson JG, Wallace R, Limacher M, et al. Elderly women diagnosed with nonspecific chest pain may be at increased cardiovascular risk. J Womens Health (Larchmt) 2006; 15:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/16\">",
"      Geraldine McMahon C, Yates DW, Hollis S. Unexpected mortality in patients discharged from the emergency department following an episode of nontraumatic chest pain. Eur J Emerg Med 2008; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/17\">",
"      Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998; 280:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/18\">",
"      Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med 2006; 119:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/19\">",
"      Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA 2005; 294:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/20\">",
"      Buntinx F, Knockaert D, Bruyninckx R, et al. Chest pain in general practice or in the hospital emergency department: is it the same? Fam Pract 2001; 18:586.",
"     </a>",
"    </li>",
"    <li>",
"     Hall, J, Roter, D. Doctors talking with patients/patients talking with doctors: improving communication in medical visits, 2nd ed, Praeger Publishers, Westport, CT 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/22\">",
"      Birdwell BG, Herbers JE, Kroenke K. Evaluating chest pain. The patient's presentation style alters the physician's diagnostic approach. Arch Intern Med 1993; 153:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/23\">",
"      Pavlik VN, Hyman DJ, Wendt JA, Orengo C. Association of a culturally defined syndrome (nervios) with chest pain and DSM-IV affective disorders in Hispanic patients referred for cardiac stress testing. Ethn Dis 2004; 14:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/24\">",
"      Challenging existing paradigms in ischemic heart disease: the NHBLI-sponsored women's ischemia syndrome evaluation (WISE). J Am Coll Cardiol 2006; 47:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/25\">",
"      D'Antono B, Dupuis G, Fortin C, et al. Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects. Am Heart J 2006; 151:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/26\">",
"      von Kodolitsch Y, Schwartz AG, Nienaber CA. Clinical prediction of acute aortic dissection. Arch Intern Med 2000; 160:2977.",
"     </a>",
"    </li>",
"    <li>",
"     McGee, S. Pulmonary embolism. In: Evidence based physical diagnosis, 2, Saunders Elsevier, 2007. p.365.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/28\">",
"      Marcus GM, Cohen J, Varosy PD, et al. The utility of gestures in patients with chest discomfort. Am J Med 2007; 120:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/29\">",
"      Davies HA, Jones DB, Rhodes J, Newcombe RG. Angina-like esophageal pain: differentiation from cardiac pain by history. J Clin Gastroenterol 1985; 7:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/30\">",
"      Berger JP, Buclin T, Haller E, et al. Right arm involvement and pain extension can help to differentiate coronary diseases from chest pain of other origin: a prospective emergency ward study of 278 consecutive patients admitted for chest pain. J Intern Med 1990; 227:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/31\">",
"      Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/32\">",
"      Berlinerblau R, Shani J. Postprandial angina pectoris: clinical and angiographic correlations. J Am Coll Cardiol 1994; 23:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/33\">",
"      Gibbons RJ. Nitroglycerin: should we still ask? Ann Intern Med 2003; 139:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/34\">",
"      Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003; 139:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/35\">",
"      Servi RJ, Skiendzielewski JJ. Relief of myocardial ischemia pain with a gastrointestinal cocktail. Am J Emerg Med 1985; 3:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/36\">",
"      Castrina FP. Unexplained noncardiac chest pain. Ann Intern Med 1997; 126:663; author reply 663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/37\">",
"      Ros E, Armengol X, Grande L, et al. Chest pain at rest in patients with coronary artery disease. Myocardial ischemia, esophageal dysfunction, or panic disorder? Dig Dis Sci 1997; 42:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/38\">",
"      Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995; 122:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/39\">",
"      Voskuil JH, Cramer MJ, Breumelhof R, et al. Prevalence of esophageal disorders in patients with chest pain newly referred to the cardiologist. Chest 1996; 109:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/40\">",
"      Ingram DA, Fulton RA, Portal RW, Aber CP. Vomiting as a diagnostic aid in acute ischaemic cardiac pain. Br Med J 1980; 281:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/41\">",
"      Tierney WM, Roth BJ, Psaty B, et al. Predictors of myocardial infarction in emergency room patients. Crit Care Med 1985; 13:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/42\">",
"      Cook DG, Shaper AG. Breathlessness, angina pectoris and coronary artery disease. Am J Cardiol 1989; 63:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/43\">",
"      Bergeron S, Ommen SR, Bailey KR, et al. Exercise echocardiographic findings and outcome of patients referred for evaluation of dyspnea. J Am Coll Cardiol 2004; 43:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/44\">",
"      Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med 2005; 353:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/45\">",
"      Friedman HZ, Weber-Bornstein N, Deboe SF, Mancini GB. Cardiac care unit admission criteria for suspected acute myocardial infarction in new-onset atrial fibrillation. Am J Cardiol 1987; 59:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/46\">",
"      Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/47\">",
"      Fleet RP, Dupuis G, Marchand A, et al. Panic disorder, chest pain and coronary artery disease: literature review. Can J Cardiol 1994; 10:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/48\">",
"      Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry 2007; 64:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/49\">",
"      Bull Bringager C, Arnesen H, Friis S, et al. A long-term follow-up study of chest pain patients: effect of panic disorder on mortality, morbidity, and quality of life. Cardiology 2008; 110:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/50\">",
"      McSweeney JC, Cody M, O'Sullivan P, et al. Women's early warning symptoms of acute myocardial infarction. Circulation 2003; 108:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/51\">",
"      McCauley J, Kern DE, Kolodner K, et al. The \"battering syndrome\": prevalence and clinical characteristics of domestic violence in primary care internal medicine practices. Ann Intern Med 1995; 123:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/52\">",
"      Clinical policy for the initial approach to adults presenting with a chief complaint of chest pain, with no history of trauma. American College of Emergency Physicians. Ann Emerg Med 1995; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/53\">",
"      Jayes RL Jr, Beshansky JR, D'Agostino RB, Selker HP. Do patients' coronary risk factor reports predict acute cardiac ischemia in the emergency department? A multicenter study. J Clin Epidemiol 1992; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/54\">",
"      Han JH, Lindsell CJ, Storrow AB, et al. The role of cardiac risk factor burden in diagnosing acute coronary syndromes in the emergency department setting. Ann Emerg Med 2007; 49:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/55\">",
"      Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 1990; 88:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/56\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/57\">",
"      Eagle KA, Isselbacher EM, DeSanctis RW, International Registry for Aortic Dissection (IRAD) Investigators. Cocaine-related aortic dissection in perspective. Circulation 2002; 105:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/58\">",
"      Murray RJ, Smialek JE, Golle M, Albin RJ. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 1989; 96:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/59\">",
"      Forrester JM, Steele AW, Waldron JA, Parsons PE. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis 1990; 142:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/60\">",
"      Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/61\">",
"      Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/62\">",
"      Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: risk factors and clinical features. J Emerg Med 1996; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/63\">",
"      Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation 2010; 122:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/64\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/65\">",
"      Sox HC Jr, Margulies I, Sox CH. Psychologically mediated effects of diagnostic tests. Ann Intern Med 1981; 95:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/66\">",
"      Norell M, Lythall D, Coghlan G, et al. Limited value of the resting electrocardiogram in assessing patients with recent onset chest pain: lessons from a chest pain clinic. Br Heart J 1992; 67:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/67\">",
"      Rude RE, Poole WK, Muller JE, et al. Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol 1983; 52:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/68\">",
"      Goldman L, Cook EF, Johnson PA, et al. Prediction of the need for intensive care in patients who come to the emergency departments with acute chest pain. N Engl J Med 1996; 334:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/69\">",
"      Brush JE Jr, Brand DA, Acampora D, et al. Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction. N Engl J Med 1985; 312:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/70\">",
"      Templeton PA, McCallion WA, McKinney LA, Wilson HK. Chest pain in the accident and emergency department: is chest radiography worthwhile? Arch Emerg Med 1991; 8:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/71\">",
"      Russell NJ, Pantin CF, Emerson PA, Crichton NJ. The role of chest radiography in patients presenting with anterior chest pain to the Accident &amp; Emergency Department. J R Soc Med 1988; 81:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/72\">",
"      Gencer B, Vaucher P, Herzig L, et al. Ruling out coronary heart disease in primary care patients with chest pain: a clinical prediction score. BMC Med 2010; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/73\">",
"      Hess EP, Thiruganasambandamoorthy V, Wells GA, et al. Diagnostic accuracy of clinical prediction rules to exclude acute coronary syndrome in the emergency department setting: a systematic review. CJEM 2008; 10:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/74\">",
"      Sanchis J, Bosch X, Bod&iacute; V, et al. Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin. Am Heart J 2010; 159:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/75\">",
"      Dekker MS, Mosterd A, van 't Hof AW, Hoes AW. Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart 2010; 96:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/76\">",
"      Suzuki T, Distante A, Eagle K. Biomarker-assisted diagnosis of acute aortic dissection: how far we have come and what to expect. Curr Opin Cardiol 2010; 25:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/77\">",
"      Sequist TD, Marshall R, Lampert S, et al. Missed opportunities in the primary care management of early acute ischemic heart disease. Arch Intern Med 2006; 166:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/78\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/79\">",
"      Kirk JD, Turnipseed S, Lewis WR, Amsterdam EA. Evaluation of chest pain in low-risk patients presenting to the emergency department: the role of immediate exercise testing. Ann Emerg Med 1998; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/80\">",
"      Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33:2092.",
"     </a>",
"    </li>",
"    <li>",
"     Braunwald, E, Mark, DB, Jones, RH, et al. Diagnosing and managing unstable angina. Quick reference guide for clinicians, number 10. AHCPR Publication No. 94-0603. Rockville, MD. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. March 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/82\">",
"      Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med 2005; 165:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/83\">",
"      Borzecki AM, Pedrosa MC, Prashker MJ. Should noncardiac chest pain be treated empirically? A cost-effectiveness analysis. Arch Intern Med 2000; 160:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/84\">",
"      Castell DO, Katz PO. The acid suppression test for unexplained chest pain. Gastroenterology 1998; 115:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/85\">",
"      Wise CM. Chest wall syndromes. Curr Opin Rheumatol 1994; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/86\">",
"      Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991; 100:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/87\">",
"      Lantinga LJ, Sprafkin RP, McCroskery JH, et al. One-year psychosocial follow-up of patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1988; 62:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/88\">",
"      Roll M, Kollind M, Theorell T. Five-year follow-up of young adults visiting an emergency unit because of atypical chest pain. J Intern Med 1992; 231:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/15/34042/abstract/89\">",
"      Chernen L, Friedman S, Goldberg N, et al. Cardiac disease and nonorganic chest pain: factors leading to disability. Cardiology 1995; 86:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6832 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34042=[""].join("\n");
var outline_f33_15_34042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY IN PRIMARY CARE POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMERGENCY RESPONSE TO CHEST PAIN IN THE OFFICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Description of chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Quality of the pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Region or location of pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Temporal elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Provocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Palliation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Normal electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Abnormal electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ALGORITHM FOR THE APPROACH TO THE DIAGNOSIS OF CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnostic algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Expanded information for algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6832|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/27/15806\" title=\"diagnostic image 1\">",
"      Aortic dissection PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/46/8928\" title=\"diagnostic image 2\">",
"      Pneumothorax PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/35/7743\" title=\"figure 1A\">",
"      Circadian pattern AMI SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/37/29278\" title=\"figure 1B\">",
"      Circadian pattern UAP nonQ MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 2\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/41/36509\" title=\"figure 3\">",
"      Risk of MI with cocaine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/58/28587\" title=\"table 1\">",
"      Etiology of chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/34/18988\" title=\"table 2\">",
"      History and LRs for MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/49/41755\" title=\"table 3\">",
"      History in musculoskeletal CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/44/8907\" title=\"table 4\">",
"      Causes of pleuritic chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/63/44027\" title=\"table 5\">",
"      Nontraditional risk factors MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/18/21803\" title=\"table 6\">",
"      ECG features of MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/59/24508\" title=\"table 7A\">",
"      ACC AHA ETT diagnosis CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/42/18093\" title=\"table 7B\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/22/21868\" title=\"table 7C\">",
"      ACC AHA choice imaging CHD diagnosis unable to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/13/28891\" title=\"table 7D\">",
"      Stress echo v stress MPI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3496?source=related_link\">",
"      Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29606?source=related_link\">",
"      Boerhaave's syndrome: Effort rupture of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9335?source=related_link\">",
"      Clinical evaluation of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41113?source=related_link\">",
"      Clinical features and diagnosis of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24342?source=related_link\">",
"      Transthoracic echocardiography for the evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_15_34043="DSM-IV-TR criteria for social anxiety disorder";
var content_f33_15_34043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F66613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F66613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR criteria for social anxiety disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A marked and persistent fear of one or more social or performance situations involving exposure to unfamiliar people or possible scrutiny by others.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The person fears that he or she will act in a way (or show symptoms of anxiety) that will be humiliating or embarrassing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to the feared social situation almost invariably provokes anxiety, which may take the form of a panic attack.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The person recognizes that the fear is excessive or unreasonable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The feared social or performance situations are avoided or endured with intense anxiety or distress.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The condition interferes significantly with the person's normal routine, occupational (or academic) functioning, or social activities or relationships, or there is marked distress about having the phobia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The fear or avoidance is not due to the direct physiological effects of a substance or a general medical condition and is not better accounted for by another mental disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If a general medical condition or another mental disorder is present, the social or performance fear is unrelated to it (eg, the fear is not of trembling in Parkinson's disease).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Specify the disorder as \"generalized\" if fears include most social situations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34043=[""].join("\n");
var outline_f33_15_34043=null;
var title_f33_15_34044="Comparison of mast cell disorders";
var content_f33_15_34044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of clinical and diagnostic features for systemic mastocytosis, mast cell activation syndromes, and idiopathic anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic mastocytosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monoclonal mast cell activation syndrome (MMAS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mast cell activation syndrome (MCAS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Idiopathic anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baseline tryptase*",
"       </td>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        Normal or mildly increased",
"       </td>",
"       <td>",
"        Normal or mildly increased",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c-kit D816V",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multifocal mast cell aggregates",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aberrant CD25",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urticaria pigmentosa",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediator release symptoms",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotensive episodes",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine N-MH or PGD",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        Increased at baseline",
"       </td>",
"       <td>",
"        Increased during symptoms",
"       </td>",
"       <td>",
"        Increased during symptoms",
"       </td>",
"       <td>",
"        Increased during symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to antimediator therapy",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    * Elevations in serum tryptase corresponding to symptoms (particularly hypotension) may be seen in all four disorders. Increases in tryptase greater than 1.2&nbsp;x baseline value + 2 ng/mL are considered significant. For example, if a patient's baseline total tryptase&nbsp;were 5 ng/mL, a value of 8 ng/mL would represent a significant increase.&nbsp;",
"    <div class=\"footnotes\">",
"     &nbsp;N-MH: N-methylhistamine; PGD2: prostaglandin D2.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34044=[""].join("\n");
var outline_f33_15_34044=null;
var title_f33_15_34045="DTaP DT TdaP Td vaccines";
var content_f33_15_34045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of and indications for diphtheria, tetanus, and pertussis vaccines for infants, children, and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diphtheria toxoid (Lf units)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tetanus toxoid (Lf units)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pertussis antigens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approved doses and age groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vaccines for children 6 weeks through 6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        DT",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        All 5 doses if there is a contraindication or precaution to pertussis vaccine (6 weeks through 6 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        DTaP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Daptacel",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         PT (10 mcg)",
"        </p>",
"        <p>",
"         FHA (5 mcg)",
"        </p>",
"        <p>",
"         PERT (3 mcg)",
"        </p>",
"        <p>",
"         FIM (5 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        All 5 doses (6 weeks through 6 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Infanrix",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <p>",
"         PT (25 mcg)",
"        </p>",
"        <p>",
"         FHA (25 mcg)",
"        </p>",
"        <p>",
"         PERT (8 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        All 5 doses (6 weeks through 6 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        DTaP combination vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Kinrix (DTaP + IPV)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <p>",
"         PT (25 mcg)",
"        </p>",
"        <p>",
"         FHA (25 mcg)",
"        </p>",
"        <p>",
"         PERT (8 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        Fifth&nbsp;dose of DTaP, fourth dose of IPV (4 through 6 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pediarix (DTap + IPV + HBV)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <p>",
"         PT (25 mcg)",
"        </p>",
"        <p>",
"         FHA (25 mcg)",
"        </p>",
"        <p>",
"         PERT (8 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        First 3 doses (6 weeks through 6 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pentacel (DTaP + IPV + Hib)",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         PT (20 mcg)",
"        </p>",
"        <p>",
"         FHA (20 mcg)",
"        </p>",
"        <p>",
"         PERT (3 mcg)",
"        </p>",
"        <p>",
"         FIM (5 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        First 4 doses (6 weeks through 4 years)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Vaccines for children &ge;7 years, adolescents, and adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Td",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 to 5",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Booster dose (&ge;7 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Tdap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adacel",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         PT (2.5 mcg)",
"        </p>",
"        <p>",
"         FHA (5 mcg)",
"        </p>",
"        <p>",
"         PERT (3 mcg)",
"        </p>",
"        <p>",
"         FIM (5 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        Booster dose (11 through 64 years)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Boostrix",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        <p>",
"         PT (8 mcg)",
"        </p>",
"        <p>",
"         FHA (8 mcg)",
"        </p>",
"        <p>",
"         PERT (2.5 mcg)",
"        </p>",
"       </td>",
"       <td>",
"        &ge;10 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Lf: limit of flocculation; DT: diphtheria and tetanus toxoids; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; PT: inactivated pertussis toxin (toxoid); FHA: filamentous hemagglutinin; PERT: pertactin (an outer membrane 69-kd protein); FIM: fimbrial proteins types 2 and 3; DTwP: diphtheria toxoid, tetanus toxoid, whole-cell pertussis vaccine; Td: tetanus, reduced diphtheria; Tdap: tetanus, reduced diphtheria, acellular pertussis; Hib: Haemophilus influenzae type b vaccine; IPV: inactivated polio vaccine; HBV: hepatitis B vaccine.",
"     <br>",
"      * The Advisory Committee on Immunization Practices recommends off-label use of Tdap vaccine for children age 7 to 10 years who are not fully vaccinated against pertussis",
"      <sup>",
"      </sup>",
"      (Centers for Disease Control and Prevention [CDC]. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap] vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13)",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Data from:",
"      <br>",
"       1. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"       <br>",
"        2. American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"        <br>",
"         3. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"        </br>",
"       </br>",
"      </br>",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34045=[""].join("\n");
var outline_f33_15_34045=null;
var title_f33_15_34046="Mechanisms cough reflex";
var content_f33_15_34046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Simplified schematic diagram of the cough reflex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Cough receptors include rapid acting receptors (RAR), slow acting receptors (SAR), C fibers, and other cough receptors. Some receptors are mechanosensitive and others are chemosensitive. Impulses from these receptors are all carried by the vagus nerve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34046=[""].join("\n");
var outline_f33_15_34046=null;
var title_f33_15_34047="Posterior vaginal wall prolapse 7";
var content_f33_15_34047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a transverse defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_15_34047=[""].join("\n");
var outline_f33_15_34047=null;
